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Summary 
 
 
The nucleolus is the nuclear compartment for ribosome biogenesis in eukaryotes. 
Inhibition of ribosome biogenesis induces the tumor suppressor p53 and inhibits cell 
cycle progression. In this thesis the molecular linkage between ribosome biogenesis 
and cell cycle control was studied. 
Recent work identified the PeBoW complex, composed of Pes1, Bop1, and WDR12, 
as an essential factor for the processing of the ribosomal 28S RNA and cell cycle 
progression. To further elucidate the function of PeBoW in cell cycle control, its 
cellular interaction partners were investigated. 
In this work Ppan was identified as PeBoW binding factor. Knock-down of Ppan 
affected cell proliferation and processing of the large ribosomal subunit RNA. The 
cellular interactions and localization of Ppan and Ppan deletion mutants in response 
to various kinds of stress were studied in detail. The σ70 and coil-coil domains in 
Ppan are required for nucleolar targeting, while the N-terminal domain of Ppan can 
be masked and unmasked, depending on the stress conditions. Strikingly, while most 
nucleolar factors translocate to the nucleoplasm or into so-called nucleolar caps 
under stress, Ppan remains in the nucleolar core, possibly involved in the 
maintenance of a basal nucleolar structure. Finally, with co-immunoprecipitation 
experiments and the Bimolecular Fluorescence Complementation assay (BiFC) the 
binding of Hdm2, a p53 specific ubiquitin ligase, to Ppan could be demonstrated. This 
observation links Ppan to p53-dependent cell cycle checkpoints.  
 
 
Zusammenfassung 
 
Der Nukleolus ist das nukleäre Kompartiment für die Ribosomenbiogenese in 
Eukaryonten. Die Inhibition der Ribosomenbiogenese aktiviert den Tumorsuppressor 
p53 und inhibiert die Zellzyklusprogression. In dieser Arbeit wurde der molekulare 
Zusammenhang zwischen Ribosomenbiogenese und Zellzykluskontrolle studiert. 
Frühere Arbeiten identifizierten den PeBoW Komplex, bestehend aus den Proteinen 
Pes1, Bop1 und WDR12, als einen essentiellen Faktor für die Prozessierung der 
ribosomalen 28S rRNA und die Zellzyklusprogression. Die zellulären 
Interaktionspartner von PeBoW wurden herangezogen, um die Funktion des 
Komplexes in der Zellzykluskontrolle zu untersuchen. 
In dieser Arbeit wurde Ppan als ein PeBoW Interaktionspartner identifiziert. Knock-
down von Ppan wirkte sich auf die Zellzyklusproliferation, sowie die Prozessierung 
der RNA der großen ribosomalen Untereinheit aus. Die zellulären Interaktionen und 
Lokalisation von Ppan und Ppan Deletionsmutanten wurden als Antwort auf 
verschiedene Stresssituationen untersucht. Die σ70 und coil-coil Domänen in Ppan 
werden für die nukleoläre Lokalisation gebraucht, die N-terminale Domäne wird 
Stress-abhängig maskiert und demaskiert. Während die meisten nukleolären 
Faktoren nach Stress ins Nukleoplasma oder die so genannten nukleolären Caps 
delokalisieren, bleibt Ppan im nukleolären Zentrum und ist möglicherweise an der 
Erhaltung der nukleolären Struktur beteiligt. Mit Co-Immunopräzipitations-
Experimenten und dem Bimolekularen Fluoreszenz Komplementationsassay (BiFC) 
konnte die Bindung von Hdm2, einer p53 spezifischen Ubiquitin-Ligase, an Ppan 
demonstriert werden. Diese Beobachtung verbindet Ppan mit p53-abhängigen 
Zellzyklus-Kontrollstellen. 
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1. Introduction 
 
1.1 From tumor suppressors to oncogenes 
 
The precise control of cell growth and cell cycle activity is critical for determining the 
size and shape of specific tissues in multicellular organisms. A complex network of 
signalling pathways integrating extracellular signals and intracellular cues controls 
cell proliferation. The ability of cells to arrest at cell cycle checkpoints as a 
consequence of cellular stress ensures genomic stability. Two categories of genes 
are involved in cell cycle and growth control and play a central role in the 
development of cancer: tumor suppressor genes protect from and oncogenes 
contribute to the development of cancer. 
 
1.2 Tumor suppressor genes 
 
Tumor suppressor genes control cell division, apoptosis and repair of damaged DNA 
(reviewed by Sherr, 2004). When tumor suppressor genes are mutated and 
inactivated, cells grow uncontrolled, which can lead to tumors. About 30 tumor 
suppressor genes have been identified so far. These can be classified as genes that 
control cell division, like the retinoblastoma tumor suppressor gene, or as genes that 
repair DNA, like the HNPCC gene (hereditary nonpolyposis colon cancer), or cell 
“suicide” genes, like p53. Because tumor suppressor genes are recessive, cells that 
contain one normal and one mutated gene still behave normally. Several 
mechanisms can lead to loss of the normal gene. For example, this may result from 
“loss of heterozygosity” or LOH. LOH applies to most abnormalities in tumor 
suppressor genes and can be provoked by either the deletion of the normal allele, 
the whole chromosome arm or even the deletion of the entire chromosome 
containing the normal allele. Furthermore, loss of a chromosome containing the 
normal allele followed by a duplication of a chromosome containing a mutated allele 
can occur. Another mechanism for inactivation of tumor suppressor genes is 
epigenetic methylation of the promoter as described e.g. for p14 Arf (Iida et al., 
2000). 
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1.3 Oncogenes 
 
Oncogenes are mutated forms of genes that cause cells to proliferate and to become 
cancerous. Mutations can cause a change in the protein structure, leading to 
increased activity or expression or loss of regulation of the oncogene. Chromosomal 
translocations can also be the cause for increased gene expression in the wrong cell 
type or at wrong times. Furthermore deregulated hybrid proteins can occur after 
chromosomal translocation, as described for adult leukemias. Mutation of microRNAs 
can additionally lead to activation of oncogenes (Esquela-Kerscher and Slack, 2006; 
Zhang et al., 2007). When proto-oncogenes mutate to oncogenes, they become 
permanently activated and the cell cycle runs out of control. Oncogenes can be 
growth factors, growth factor receptors, signal transducers, transcription factors or 
programmed cell death regulators. 
 
1.4 c-Myc 
 
The proto-oncogene c-myc is part of a transcription factor network that regulates 
cellular proliferation, replication, growth, differentiation and apoptosis. Generally, c-
Myc expression closely correlates with the proliferation status of a cell: in quiescent 
cells, c-Myc is almost undetectable, whereas upon mitogen stimulation, mRNA and 
protein levels are rapidly induced (Henriksson and Luscher, 1996). c-Myc is down-
regulated during differentiation.  Deregulated expression of c-myc has been found 
through genomic aberrations in a wide array of B-cell-specific malignancies and 
several other types of neoplasias (Boxer and Dang, 2001). c-Myc is a transcription 
factor controlling the expression of many genes associated with progression through 
the cell cycle and synthesis of cellular components preparing cells for division. c-Myc 
directly regulates ribosome biosynthesis through the transcription of genes coding for 
factors involved in ribosome maturation and assembly (Schuhmacher et al., 2001; 
Schlosser et al., 2003). c-Myc associates with ribosomal DNA and stimulates RNA 
polymerase I transcription in response to mitogenic signals (Arabi et al., 2005; 
Grandori et al., 2005). 
The aim of this thesis is the functional analysis of c-Myc target genes with nucleolar 
function. The focus will be on the linkage of ribosome biogenesis and cell cycle 
control and particular on the mechanism and factors coupling these two processes. 
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1.5 Conventional roles of the nucleolus 
 
The nucleolus is a distinct sub-nuclear compartment where all eukaryotes synthesize 
their ribosomes (reviewed by: Leary and Huang, 2001; Shaw and Doonan, 2005; 
Raska et al., 2006; Boisvert et al., 2007). It has been estimated that a growing HeLa 
cell produces about 7.500 ribosomal subunits per minute, which requires 
approximately 300.000 ribosomal proteins and numerous associations and 
dissociations with trans-acting factors, putting an immense demand on the cellular 
machinery (Lewis and Tollervey, 2000). The nucleolus is formed around genetic loci 
on the chromosomes called nucleolar organizing regions (NORs), which consist of 
tandemly repeated genes for rRNA. Human cells have NORs on the short arms of 
the five acrocentric chromosomes (13, 14, 15, 21 and 22). They contain about 400 
ribosomal genes (r-genes). Each r-gene repeat forms the 47S pre-rRNA precursor 
and consists of 18S, 5.8S and 28S rRNA coding sequences, transcribed internal and 
external spacers (ITS and ETS) and non-transcribed intergenic spacers (Fig. 1).  
 
 
Fig. 1. Mammalian 47S pre-rRNA precursor. The 18S, 5.8S and 28S rRNAs are separated 
by two internal transcribed sequences (ITS-1 and -2) and flanked by two external transcribed 
sequences (5´ETS and 3´ETS). 
 
 
The coordinated activity of RNA polymerases I, II and III is required for ribosome 
biogenesis. The RNA polymerase I transcribes ribosomal DNA for the 18S, 5.8S and 
28S rRNA, the RNA polymerase II transcribes the genes for ribosomal proteins and 
accessory factors and the RNA polymerase III is important for transcription of 5S 
rDNA.  
Although the nucleolus in not enclosed in a membrane, it does exhibit three distinct 
compartments, namely fibrillar centres (FC), the dense fibrillar component (DFC) and 
the granular component (GC). The most important step of ribosome biosynthesis is 
the transcription of rDNA by RNA polymerase I (RNA pol I), which takes place at the 
border between the fibrillar centre and dense fibrillar component. The product of RNA 
pol I transcription is a long rRNA precursor (pre-rRNA), which is modified by 200 
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nucleotide methylations and pseudouridylations. The three mature rRNAs are 
produced through sequential cleavage by endo- and exonucleases in the dense 
fibrillar component of the nucleolus. Recent evidence was given for the coordinated 
action of rDNA transcription and processing of the ribosomal RNAs (Gallagher et al., 
2004; Granneman and Baserga, 2005; Kopp et al., 2007). The assembly of 5.8S with 
28S and 5S rRNA into the 60S subunit occurs in the granular component, as well as 
the assembly of 18S into the 40S ribosomal subunit. Both subunits are then exported 
to the cytoplasm to form mature ribosomes. 
 
1.6 The nucleolus during the cell cycle 
 
The nucleolus is a dynamic structure: it disassembles when cells enter mitosis and 
reassembles during the G1 phase of the cell cycle. At the beginning of the prophase 
components of the rDNA transcription machinery are hyperphosphorylated and 
transcription is downregulated. The RNA pol I transcription machinery remains 
associated with the active NORs (Roussel et al., 1996), whereas the rRNA 
processing machinery leaves the nucleoli (Leung et al., 2004). Some processing 
factors are released into the cytoplasm, whereas others become attached to the 
surface of condensed chromosomes, which is called the perichromosomal region 
(PR) (Gautier et al., 1992). This PR consists of rRNA processing components, the 
small nucleolar RNA U3 (U3 snoRNA), pre-rRNA, fibrillarin and non-nucleolar 
proteins. In anaphase, rRNA-processing components are either associated with the 
chromosomes or are packaged in the cytoplasm into nucleolar-derived foci (NDF) 
(Dundr and Olson, 1998). NDF contain early and late rRNA-processing factors, the 
U3 snoRNA and partially processed pre-rRNAs. In the late anaphase and early 
telophase, the rDNA transcription is reactivated (Sirri et al., 2000). Small particles 
dissociate from the NDF and pass into the nucleus through the newly formed nuclear 
membrane. The number of NDFs decreases until they completely disappear at the 
end of the G1 phase (Dundr et al., 2000). Most of the components of the NDF are 
transferred to newly formed structures, the pre-nucleolar bodies (PNBs), which are 
associated with the chromosomes. The PNBs contain, similar to the NDF, processing 
proteins, snoRNAs and partially processed pre-rRNAs (Savino et al., 2001). The 
perichromosomal region breaks down and most components are incorporated into 
the PNBs, whereas other processing components are distributed in the nucleoplasm 
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(Hernandez-Verdun, 2006). During the G1 phase nucleoli are reassembled. 
Processing components of the PNB are subsequently released in a defined order 
and recruited to nucleoli. First, components, which have early roles in the pre-rRNA 
processing are recruited, like fibrillarin, and later, proteins involved in late steps of 
rRNA processing move from the PNBs to the nucleoli (Sirri et al., 2002). Finally the 
rRNA transcription machinery and rRNA processing machinery reassemble on the 
rDNA and the NORs move together in the nucleoplasm and fusion to new functional 
nucleoli. 
 
1.7  PeBoW and the connection to Ppan 
 
Pes1, Bop1 and WDR12 are members of the previously characterized human 
PeBoW complex (Hölzel et al., 2005; Rohrmoser et al., 2007) with nucleolar function, 
and are essential for ribosome biogenesis. All three factors are encoded by c-Myc 
target genes. The PeBoW complex is required for the processing and maturation of 
the ribosomal large subunit 28S rRNA (Hölzel et al., 2005, Grimm et al., 2006). The 
connection between ribosome biogenesis and cell cycle control was the reason to 
study this complex in detail. In particular, interaction partners of PeBoW were 
investigated for further characterization. Since nothing was known about mammalian 
interaction partners, examination of binding partners of the homologous complex in 
yeast was performed. Nop7, Erb1 and Ytm1 are homologues of mammalian Pes1, 
Bop1 and WDR12. For Nop7 230 interactions have been described, 164 for Erb1 and 
125 for Ytm1 (www.yeastgenome.org; www.thebiogrid.org). Nop7, Erb1 and Ytm1 
have 35 common interaction partners in yeast. Thirteen of the thirty-five interaction 
partners attracted my attention, because they have homologues in human and are 
described as c-Myc targets (Guo et al., 2000; Schlosser et al., 2002; Li et al., 2003; 
Marinkovic et al., 2004) (Tab. 1). 
Table 1 contains several interesting candidate factors. In this work we decided to 
work with Ppan for two reasons. Firstly, the function of Ssf1 in yeast is well described 
and secondly, interesting preliminary observations were made for Ppan in the fruit-fly 
and a human cancer cell line, ascribing Ppan tumor suppressor gene functions. 
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Tab. 1. Common yeast interaction partners of Nop7, Erb1 and Ytm1 and their 
homologues in human, described as c-Myc targets. 
 
yeast function human function 
Dbp10 DEAD box RNA helicase 
(Burger et al., 2000) 
DDX54 unknown 
Ebp2 required for 60S subunit 
synthesis (Tsujii et al., 2000) 
EBP2 interacts with the EBV nuclear 
antigen 1 (Shire et al., 1999) 
Glc7 catalytic subunit of type 1 
serine/threonine protein 
phosphatase, involved in many 
processes (Feng et al., 1991) 
PPP1CC 
 
regulates an enormous variety 
of cellular functions  
(Cohen, 2002) 
Has1 helicase, required for snoRNA 
release from pre-rRNA  
(Liang and Fournier, 2006) 
DDX18 helicase; important for cell 
proliferation  
(Dubaele and Chène, 2007) 
Mak21 required for 60S ribosomal 
subunit biogenesis  
(Edskes et al., 1998) 
CBF  involved in cell proliferation and 
differentiation  
(Ramji and Foka, 2002) 
Nop1 associated with snoRNA; 
required for rRNA processing 
(Schimmang et al., 1989) 
fibrillarin binds U3, U8 and U13 snoRNA; 
required for pre-rRNA proces-
sing (Kass et al., 1990) 
Nog1 required for 60S ribosomal 
subunit biogenesis  
(Kallstrom et al., 2003) 
Nog1 assembly of pre-60S subunits, 
processing of pre-rRNA inter-
mediates (Lapik et al., 2007) 
Nop2 60S subunit synthesis  
(Hong et al., 1997) 
p120 proliferation marker, binds 
rRNA (Gustafson et al., 1998) 
Nug1 associates with pre-60S 
ribosomal particles  
(Bassler et al., 2006 ) 
NST controls cell proliferation in 
stem cells and cancer cells 
(Tsai and McKay, 2002) 
Rpf1 Brix-domain containing protein BXDC5 unknown 
Rrp1 involved in 60S subunit 
synthesis (Horsey et al., 2004) 
Nop52 predicted role in generation of 
28S rRNA (Savino et al., 1999) 
Rrp5 40S and 60S subunit synthesis 
(Venema and Tollervey, 1996) 
NFBP processing of rRNA  
(Sweet et al., 2008) 
Ssf1 prevents premature processing 
of pre-rRNA, involved in 
maturation of 25S  
(Fatica et al., 2002) 
Ppan functions as a tumor 
suppressor (Welch et al., 2000) 
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1.8 Yeast Ssf1 
 
Yeast Ssf1 was originally identified in a screen for altered sensitivity in the response 
to mating pheromone (Yu and Hirsch, 1995; Kim and Hirsch 1998). However, in 
these studies Ssf1 localized to the nucleolus, suggesting an alternative or additional 
role for the protein in ribosome synthesis in yeast. Ssf1 and Ssf2 form a gene pair 
with 94% identity. Cells containing null alleles of either Ssf1 or Ssf2 show no obvious 
phenotype, but disruption of both genes is lethal (Yu and Hirsch, 1998). Yeast Ssf1 is 
34% identical and 58% similar to human Ppan, indicating its evolutionary 
conservation. Ssf1 is a member of a conserved gene family, including Ssf2, Imp4, 
Rpf1, Rpf2 and Brx1 (Fatica et al., 2002; Eisenhaber et al., 2001). All proteins of this 
family are implicated in ribosome biogenesis and contain a conserved domain, the 
Brix domain (Biogenesis of ribosomes in Xenopus). In yeast Ssf1 is involved in the 
synthesis of the large subunit rRNAs (Fatica et al., 2002).  
 
1.9  The function of Ssf1 in ribosome biogenesis 
 
In yeast, ribosome biogenesis is initiated by the transcription of the 35S pre-rRNA 
precursor and multiple coordinated processing steps to form the mature 18S, 5.8S 
and 25S rRNA (Fig. 2). The yeast 35S pre-rRNA precursor contains the sequences 
for the mature rRNAs, two internal transcribed sequences 1 and 2 (ITS-1 and ITS-2) 
and two external transcribed spacers (5’ ETS and 3’ ETS). The processing of the pre-
rRNA precursor occurs sequentially at specific cleavage sites (Fig. 2 and 3). 
Normally, the 35S pre-rRNA precursor is cleaved to produce the 32S pre-RNA, which 
in turn is processed to give the 20S and 27SA pre-rRNA forms (Fig. 3). The 27SA 
pre-rRNA is converted to 27SB and then to 25S rRNA and 5.8S rRNA, whilst the 20S 
pre-rRNA is converted to 18S rRNA. A detailed description of the complicated 
cleavage sequence is described in figure 3. 
The depletion of factors involved in ribosome biogenesis leads to abnormal rRNA 
processing, with accumulation of different rRNA precursor forms (Venema and 
Tollervey, 1999). For instance, the depletion of Ssf1 leads to an abnormal pre-rRNA 
processing and formation of aberrant rRNA precursors (Fatica et al., 2002). In Ssf1-
depleted cells the kinetics of 18S rRNA are not changed, instead the pathway leading 
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Fig. 2. Structure and processing sites of the Saccharomyces cerevisiae 35S pre-rRNA. 
The cleavage sites are described by letters and numbers. Ssf1-depleted cells accumulate 
aberrant RNA products, which extend from the 5’ end to cleavage site A3 (23S) or D, or 
accumulate a fragment spanning between the cleavage sites A2 and C2. 
 
 
to 5.8S and 25S is affected. An aberrant product of 23S appears, which originates 
from cleavage of the 35S pre-rRNA at site A3, when the cleavages at sites A0, A1 and 
A2 are delayed (Fig. 2 and 3). The delay in cleavage at sites A0 to A2 is probably 
secondary to the defect of the large subunit synthesis. Similar defects have also 
been described for other factors involved in 60S subunit biogenesis (Venema and 
Tollervey, 1999). As a consequence the 35S rRNA precursor accumulates, while the 
32S and 27SA pre-rRNAs is less abundant and the mature 25S rRNA is greatly 
reduced. Furthermore, an aberrant RNA fragment also accumulates, which extends 
from the end of the 5’ ETS to site D. In addition an RNA species that extends from A2 
to C2 is accumulated in Ssf1 depleted cells. It has therefore been concluded that Ssf1 
is necessary to prevent premature processing at site C2 and to maintain the normal 
order of pre-rRNA processing. 
 
1.10  Known interaction partners of Ssf1  
 
Ssf1 associates with 27S pre-rRNA in a preribosomal particle containing additionally 
twenty-three non-ribosomal nucleolar proteins, among them Nop7, Erb1 and Ytm1 
(Fatica et al., 2002). The list of interaction partners of Ssf1 currently contains 51 
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Fig. 3. Pre-rRNA processing pathway in Saccharomyces cerevisiae (adapted from 
Fatica et al., 2002). In wild-type cells, the 35S pre-rRNA is first cleaved at site A0, producing 
the 33S pre-rRNA; this molecule is rapidly cleaved at site A1 to produce the intermediate 
32S. 32S is cleaved at site A2, releasing 20S and 27SA2. 27SA2 is then processed via two 
alternative pathways. It is either cut at site A3 to produce 27SA3, which is then trimmed to site 
B1S, producing 27SBS, or it can be processed to 27SBL by an as yet unknown mechanism. 
27SBS and 27SBL are matured to the 5.8S and 25S following identical pathways. Cleavage at 
site C2 generates the 7S and 26S pre-rRNAs. The 7S pre-rRNA is digested 3’ to 5’ to 6S pre-
rRNA and then to the mature 5.8S rRNA. The 26S pre-rRNA is digested 5’ to 3’ to the 25S 
pre-rRNA and then to the mature 25S rRNA. (For a review of pre-rRNA processing and the 
known processing enzymes, see Venema and Tollervey, 1999.) The vertical thick line 
indicates strong associations between the Ssf1p protein and RNA species and the dashed 
line shows weak associations. 
 
 
factors (Gavin et al., 2002; Ho et al., 2002; Krogan et al., 2006; Lebreton et al., 
2006). Of these factors, 31 are directly involved in biogenesis of the large ribosomal 
subunit, 7 are ribosomal proteins, 1 has unknown functions and the remaining 12 
have other functions in the cell. 
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1.11 Peter Pan in Drosophila 
 
The gene peter pan (ppan) was identified in a screen for larval growth-defective 
mutants of the fruit-fly Drosophila melanogaster. Ppan mutant larvae did not grow, 
like Peter Pan, the homonymous boy who never wanted to grow up in the story of 
James M. Barrie. The same larvae showed minimal DNA replication but could survive 
well after their heterozygotic siblings had pupariated (Migeon et al., 1999).  It was the 
first evidence that Ppan is required for some aspects of cell differentiation as well as 
for cellular growth. 
 
1.12 Human Ppan 
 
Ppan attracted attention in a study showing that it plays a role in tumor suppression. 
Welch and his colleagues used a library of hairpin ribozymes to identify genes 
involved in anchorage-dependent growth (Welch et al., 2000). Human HF cells, a 
non-transformed revertant of HeLa cells, have lost the ability to grow in soft agar, 
probably due to the activation of a tumor suppressor (Boylan et al., 1996). 
Nevertheless, HF cells could grow again in soft agar, when Ppan was depleted by 
application of the specific ribozyme. The authors proposed that Ppan is part of a 
pathway that provides a cell with information about its substrate contact and may be 
involved in the metastatic potential of transformed cells. Overexpression of Ppan 
induced toxicity in HeLa cells, suggesting that overproduction could possibly lead to 
tumor-specific cell death. 
Communi et al. (2001) isolated during a screen of a human placenta library a 
chimeric transcript consisting of Ppan and P2Y11 (SSF1-P2Y11). The P2Y11 gene is 
adjacent to ppan at chromosome 19p13.2 and codes for a receptor belonging to the 
P2Y family of G-protein-coupled nucleotide receptors. The functional significance of 
the chimera remains unclear. The presence of chimeric messengers resulting from 
intergenic splicing is not commonly observed in normal mammalian cells. The 
authors postulated that intergenic splicing could be a mechanism for generating new 
multidomain proteins and could therefore have major evolutionary implications. 
In the year 2004, Ppan was placed on the list of c-Myc target genes with a potential 
role in lymphomagenesis (Marinkovic et al., 2004). In this study the authors searched 
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for direct Myc target genes using different mouse T and B cell lymphoma cell lines 
transformed by a conditional Myc-allele. Ppan was found to be upregulated by c-Myc. 
 
1.13  Structure of the human Ppan protein  
 
The major characteristic in the Ppan protein is the occurrence of a large globular Brix 
domain, spanning between amino acids 30-300 (Fig. 4). The Brix domain contains a 
RNA-binding motif, called σ70 like motif, which is a short sequence highly related to a 
DNA binding motif of the E. coli σ70 transcription factors. The σ70 like motif of the 
Brix domain is unique to a superfamily of proteins from yeast to human required for 
ribosome biogenesis and confers RNA binding (Wehner and Baserga, 2002). The N-
terminal part of the Brix domain contains 2 putative nuclear localization sites (NLS) 
(amino acids 51-67 and 113-129) and the C-terminal part harbours the σ70-like motif 
(amino acids 270 to 285). The Brix domain is followed by a coil-coil domain (amino 
acids 304-342), which is known to mediate protein-protein interactions and subunit 
oligomerization (Burkard et al., 2001). At the C-terminus of Ppan two predicted AT-
hook domains (amino acids 425-435 and 460-470) are located. These domains are 
present in proteins preferentially binding to the minor groove of stretches of A-T-rich 
sequences (Reeves and Nissen, 1990). A third putative NLS (amino acids 449-465) 
is embedded between the two AT-hook domains. Ppan has four phosphorylated 
residues: S238, S240, T370 (Dephoure et al., 2008) and S359 (Beausoleil et al., 
2004). According to the SUMOplotTM prediction database, Ppan possesses 4 putative 
sumoylation sites at lysine-residues at position K413 with high probability and 
positions K217, K336 and K435 with low probability.  
 
 
1.14 Ppan’ s homology across different species 
 
Protein database searches revealed Ppan homologs in four different species (Tab. 
2). All of these contain a Brix domain. 
The major difference between human Ppan and yeast Ssf1 are the two predicted AT-
hook domains at the far C-terminus of the human Ppan protein. Most probably these 
evolutionary younger domains enable Ppan to have additional functions in 
mammalian cells. 
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Fig. 4. (a) Schematic model and (b) amino acid sequence of human Ppan with 
characteristic features. According to UniProt (http://expasy.proteome.org.au/uniprot) there 
are two isoforms of Ppan: Q9NQ55-1 (473 amino acids) and Q9NQ55-2 (460 amino acids). 
In isoform Q9NQ55-2 amino acids at positions 444 to 456 are missing. There is no 
experimental evidence for the existence of the isoform 2. Only the isoform Q9NQ55-1 (full 
length) of Ppan was studied in this thesis. (adapted and modified from www.expasy.org). 
 
 
Tab. 2. Ppan homologues in different species 
Species Reference protein Protein accession 
number 
Identity % Length (aa) 
R. norvegicus Ppan homolog NP_001011980.1 88.1 463 
M. musculus Ppan homolog NP_663585.1 84.8 468 
D. melanogaster Ppan CG5786-PA NP_476979.1 46.1 406 
S. cerevisiae Ssf1 NP_011933 34.5 455 
 
 
a 
b 
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1.15 Non-conventional roles of the nucleolus 
 
In addition to ribosome biogenesis the nucleolus is involved in many other aspects of 
cellular activities, like signal recognition particle assembly, modulation of telomerase 
function, modification of small nuclear RNAs and cell cycle regulation (Olson et al., 
2002). The nucleolus is not a static structure and its components move constantly 
and exchange with the surrounding nucleoplasm (Phair and Misteli, 2000; Olson and 
Dundr, 2005). Nucleoli respond to changes in cellular growth rate and metabolic 
activity, which indicates that they constantly receive and respond to signalling events. 
It is therefore not surprising that many nucleolar proteins are regulated by c-Myc 
(Schlosser et al., 2003).  
Signal recognition particle (SRP) is a translational arrest machine that binds to the N-
terminal signal peptide sequence of nascent secretory and membrane proteins, and 
blocks the peptidyl-transferase activity of 28S rRNA. The SRP of higher eukaryotes 
contains an essential RNA component and 6 proteins. The SRP RNA is localized and 
processed in the nucleolus (Jacobson and Pederson, 1998).  
The telomerase is a reverse transcriptase ribonucleoprotein enzyme that synthesizes 
telomeric DNA repeats at the ends of eukaryotic chromosomes. The localization of 
telomerase is dynamic throughout the cell cycle. In early S-phase the key 
components of telomerase localize in nucleoli (Tomlinson et al., 2006). The reason 
for this localization is not known at the moment. The nucleolus also serves for 
processing of other small nuclear RNAs (snoRNAs), including tRNA. The small 
nuclear RNA U6, normally localizing in nucleoplasmic foci, was found to be 
associated in nucleoli with fibrillarin, which directs the methylation of the U6 snoRNA 
(Pederson, 1998). Furthermore it was shown that nucleolar trafficking is essential for 
nuclear export of intronless herpesvirus mRNA (Boyne and Whitehouse, 2006). 
Recent studies regarding proteins involved in cell cycle regulation suggest that the 
nucleolus might function as a “prison”. Sequestration in the nucleolus prevents 
proteins from reaching their targets in other regions of the cell (Visintin and Amon, 
2000). For example, the phosphatase Cdc14 localizes during mitotic interphase and 
metaphase in nucleoli of yeast cells, whereas at anaphase it spreads to the nucleus 
and cytoplasm, where it inactivates mitotic kinases, leading to exit from mitosis 
(Visintin et al., 1998). 
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1.16 Nucleolus and the tumor suppressor p53 
 
In a hallmark study, Rubbi and Milner (2003) proposed that the nucleolus is a major 
stress sensor that transmits signals for regulation of activity of the tumor suppressor 
p53. The tumor suppressor and transcription factor p53, termed the “guardian of the 
genome”, can induce cell-cycle arrest or apoptosis in response to a variety of cellular 
stress signals. These properties are exploited in anti-cancer therapy, mainly by 
triggering a p53 response through genotoxic stress (Weinstein et al., 1997). The 
importance of p53 is underlined by the fact that the protein has been shown not to 
function properly in most human cancers. Approximately 50% of sporadic human 
tumors harbour somatic mutations in the p53 gene locus. p53 is inactivated most 
frequently by mutation in the DNA binding domain. Furthermore, mislocalization of 
the protein can block its proper function. Viral infections can cause an inactivation of 
p53, when viral oncogenes bind and inactivate p53 or stimulate its degradation 
(reviewed in Vogelstein et al., 2000).   
p53 is a short-lived protein that is present in cells at a barely detectable level. 
Although it is continuously synthesized, p53 is subjected to fast degradation, in order 
to maintain low levels of the protein in the cell. Upon exposure of cells to various 
forms of exogenous or endogenous stress, the cellular amount of p53 rapidly 
increases by blocking its degradation. Activated p53 binds to promoters of target 
genes and activates the transcription of e.g. p21, mdm2 and BAX (Levine, 1997; 
Vogelstein et al., 2000; Zhao et al., 2000). Depending on the cellular stress p53 
induces cell cycle arrest or apoptosis. This is thought to be possible through 
differences in its binding affinity to the promoters of target genes. When damage is 
repairable, p53 binds preferably to genes promoting cell cycle arrest, like p21. Is the 
damage more severe, p53 targets promoters of genes responsible for apoptosis 
(Chen et al., 1996; Ludwig et al., 1996). 
The degradation of the p53 protein is promoted by Hdm2 (Mdm2 in mouse), which is 
an E3 ubiquitin ligase and mono-ubiquitinates p53. Ubiquitination of p53 marks it for 
export and degradation in the cytoplasm. Stabilization of p53 can be achieved when 
the formation of the Hdm2-p53 complex is blocked for example by posttranslational 
mechanisms. The p53 protein is targeted by modifying kinases and acetyl-
transferases. Different types of cellular stress activate distinct kinases and acetyl-
transferases (reviewed by Ljungman, 2000), to modify p53 at different residues, 
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which might explain the different p53 response to each stress situation (Zhao et al., 
2000). For example, ionizing radiation induces on p53 phosphorylation on serine 
residues Ser15 and Ser37 by the kinase ATM, which blocks Hdm2 binding 
(Sakaguchi et al., 1998). The acetyltransferase p300 functions in the apoptotic 
response to ionizing radiation and acetylates lysine at amino acid position 382 of 
p53, leading to increased stability of p53 (Gu and Roeder, 1997). 
Disruption of the nucleolus and aberrant ribosome biogenesis results in an increase 
of p53 and cell-cycle arrest (Rubbi and Milner, 2003). But how is a disruption of the 
nucleoli transmitted to p53? Several models for the stabilization of p53 in response to 
nucleolar perturbation are discussed. 
One model suggests that the nucleolus is required for the export of the p53-Hdm2 
complex into the cytoplasm for degradation and that disruption of the nucleolus 
inhibits the export (Tao and Levine, 1999; Sherr and Weber, 2000). The model of 
Hdm2-p53 complexes „riding the ribosome“ (Sherr and Weber, 2000) is supported by 
the observation that p53 can be covalently linked to 5.8S rRNA and associates with a 
subset of ribosomes (Fontoura et al., 1992 and 1997). Furthermore, the activity of 
p53 is regulated by several nucleolar proteins (Fig. 5):  
• p14Arf binds to Hdm2 and sequesters it to the nucleolus, liberating thereby 
p53 in the nucleoplasm, which then becomes activated (Weber et al., 1999 
and 2000). p14Arf also translocates from the nucleolus into the nucleoplasm 
when cells are treated with inhibitors of cyclin-dependent protein kinases with 
concomitant increase in levels of p53 (David-Pfeuty and Nouvian-Dooghe, 
2002).  
• Nucleophosmin (NPM) is a multifunctional protein involved in ribosome 
biogenesis and regulates the stability and transcriptional activity of p53 
(Colombo et al., 2002). Nucleophosmin interacts with Hdm2 and inhibits its 
activity preventing the ubiquitination of p53 (Kurki et al., 2004).  
• Nucleolin, is mobilized from the nucleolus to the nucleoplasm under stress 
conditions, where it interacts directly with p53 (Daniely and Borowiec, 2000). 
• Nucleostemin (NST), a GTP-binding protein, shuttles between the nucleolus 
and nucleoplasm and seems also to be involved in regulating p53 activity 
(Tsai and McKay, 2002).  
• The ribosomal proteins S7 (Chen et al., 2007), L5 (Marechal et al., 1994), L11 
(Lohrum et al., 2003, Zhang et al., 2003) and L23 (Jin et al., 2004) interact 
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with Hdm2 after ribosomal perturbation resulting in accumulation of p53 and 
cell cycle arrest.  
• Recent evidence demonstrates the nuclear protein PML regulating p53 
stability after DNA damage through sequestration of Hdm2 to the nucleoli 
(Bernardi et al., 2004). 
 
 
Fig. 5. Binding of Hdm2 by several nucleolar factors activates p53. p14Arf, 
nucleophosmin, ribosomal proteins (r-proteins) S7, L5, L11 and L23, and PML sequester 
Hdm2 to the nucleolus after nucleolar perturbation. Nucleolin and NST bind to p53 in the 
nucleoplasm and regulate its activity. p53, which is no longer interacting with Hdm2, binds 
subsequently to target genes implicated in apoptosis of cell cycle arrest. 
 
 
The cross talk between the p53 pathway and the nucleolus has been tried to be 
explained by several models. Many proteins seem to regulate Hdm2, which indicates 
a high complexity of the nucleolar stress response machinery. The exact mechanism 
how the nucleolus is linked to the cell cycle control remains unknown and 
speculative. Other nuclear and nucleolar factors could probably be involved in the 
regulation of p53 in response to nucleolar stress. 
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1.17 The goal of this work 
 
The previously characterized PeBoW complex consisting of Pes1, Bop1 and WDR12 
has been shown to play a crucial role in ribosome biogenesis as well as cell cycle 
progression. Imbalanced levels of these proteins impair ribosome biogenesis and 
activate a p53-dependent checkpoint, leading to a reversible block of proliferation. 
Aiming to understand the connection between ribosome biogenesis and cell cycle 
regulation, Ppan was chosen to further elucidate this checkpoint. Studies in fruit-fly 
and human indicated a role of Ppan in cell differentiation and growth as well as tumor 
suppression. These characteristics, together with the finding that the yeast 
homologue of Ppan, Ssf1, interacts with the trimeric yeast complex of Nop7, Erb1, 
and Ytm1, which is the homologue of PeBoW, prompted us to investigate the 
function of Ppan in human cells in detail. In particular, a possible role of Ppan for the 
linkage of impaired ribosome biogenesis and p53-mediated cell cycle arrest should 
be investigated. 
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2. Material and Methods  
  
Material  
  
2.1 Reagents  
  
1-kb-DNA Ladder Invitrogen, Karlsruhe 
β-Mercaptoethanol Sigma-Aldrich, Hamburg 
[γ-32P] dATP, 3000 µCi/mmol Hartmann-Analytik, Braunschweig 
[α-32P] dCTP, 3000 µCi/mmol Hartmann-Analytik, Braunschweig 
Acrylamid Rotiphorese® Gel 30 (37, 5:1) Carl Roth, Karlsruhe 
Actinomycin D Sigma-Aldrich, Hamburg 
Agar GibcoTM, Invitrogen, Karlsruhe 
Agarose Invitrogen, Karlsruhe 
Ampicillin  Carl Roth, Karlsruhe 
Ammoniumperoxodisulfat (APS) Carl Roth, Karlsruhe 
Bovine serum albumin Fraktion V Carl Roth, Karlsruhe 
Bromophenol blue Sigma-Aldrich, Hamburg 
Calf Intestine Alkaline Phosphatase (CIAP) MBI Fermentas, St. Leon-Rot 
Cycloheximide Sigma-Aldrich, Hamburg 
DAPI  Sigma-Aldrich, Hamburg 
Diethyl Pyrocarbonate (DEPC)  Sigma-Aldrich, Hamburg 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Hamburg 
Dithiothreitol (DTT) Carl Roth, Karlsruhe 
DNAse I Roche, Mannheim 
DMEM Invitrogen, Karlsruhe 
dNTP  Promega, Mannheim 
Doxycycline Sigma-Aldrich, Hamburg 
ECLTM Plus Western Blotting Detection Reagent GE-Healthcare, München 
ECLTM Western Blot Detection Reagent GE-Healthcare, München 
EDTA Carl Roth, Karlsruhe 
EGTA Carl Roth, Karlsruhe 
Ethanol p.A. Merck, Darmstadt 
Ethidium bromide Sigma-Aldrich, Hamburg 
Fetal calf serum (FCS) PAA, Invitrogen, Karlsruhe 
Fluorescent Mounting Medium DakoCytomation, Hamburg 
5-Fluorouracil Sigma-Aldrich, Hamburg 
Formaldehyde 37 % Carl Roth, Karlsruhe 
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Formamide Carl Roth, Karlsruhe 
FuGene transfection reagent Roche, Mannheim 
L-Glutamine PAA, Invitrogen, Karlsruhe 
Glycerin 87 % Carl Roth, Karlsruhe 
Glycine Carl Roth, Karlsruhe 
HEPES Merck, Darmstadt 
HCl Merck, Darmstadt 
Hygromycin B Invitrogen, Karlsruhe 
Immersion oil „Immersol“ 518F fluorescence free Carl Zeiss, Göttingen 
Isopropanol p.A. Carl Roth, Karlsruhe 
Kanamycin Sigma-Aldrich, Hamburg 
Magnesium chloride Merck, Darmstadt 
Manganese chloride Merck, Darmstadt 
Methanol p.A. Merck, Darmstadt 
MG-132 Sigma-Aldrich, Hamburg 
Milk powder Carl Roth, Karlsruhe 
MOPS 3-(N-Morpholino)-propansulfonsäure Sigma-Aldrich, Hamburg 
Oligofectamin Invitrogen, Karlsruhe 
Oligo-dT primer MBI Fermentas, St.Leon-Rot 
Oligonucleotids for PCR Metabion, Martinsried 
Sigma-Aldrich, Hamburg 
OptiMEM Invitrogen, Karlsruhe 
Paraformaldehyde Sigma-Aldrich, Hamburg 
Penicillin/streptomycin PAA, Invitrogen, Karlsruhe 
Pfu DNA Polymerase Promega, Mannheim 
Phenylmethylsulfonylfluorid (PMSF) Carl Roth, Karlsruhe 
Taq DNA Polymerase Invitrogen, Karlsruhe 
PIPES Merck, Darmstadt 
Platinum® Pfx Polymerase Invitrogen, Karlsruhe 
PMSF Carl Roth, Karlsruhe 
Polyethylenglycol (PEG) 6000 MBI Fermentas, St. Leon-Rot 
Polyfect Qiagen, Hilden 
T4-Polynucleotidekinase MBI Fermentas, St. Leon-Rot 
Potasium chloride Merck, Darmstadt 
Potasium hydroxide Merck, Darmstadt 
Protein G-Agarose GE-Healthcare, München 
Proteinase inhibitor cocktail Roche, Mannheim 
Puromycine Sigma-Aldrich, Hamburg 
Restriction enzymes MBI Fermentas, St. Leon-Rot 
New England Biolabs, Frankfurt 
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RNAse A Roche, Mannheim 
RNAsin RNAse inhibitor MBI Fermentas, St. Leon-Rot 
Rubidium chloride Merck, Darmstadt 
SDS Carl Roth, Karlsruhe 
Sodium acetate Carl Roth, Karlsruhe 
Sodium chloride Merck, Darmstadt 
Sodium hydroxide Carl Roth, Karlsruhe 
Sodium phosphate dibasic anhydrous  Merck, Darmstadt 
Sodium molybdate Carl Roth, Karlsruhe 
Sodium orthovanadate  Carl Roth, Karlsruhe 
Sodium phosphate monobasic monohydrate Merk, Darmstadt 
Sparfloxacine Sigma Aldrich, Hamburg 
Sucrose ICN, Northeim 
T4 DNA Ligase  Invitrogen, Karlsruhe 
TEMED Carl Roth, Karlsruhe 
TriFast Peqlab, Erlangen 
Tris Base Carl Roth, Karlsruhe 
Triton X-100 Sigma-Aldrich, Hamburg 
Trypsin-EDTA GibcoTM, Invitrogen, Karlsruhe 
Tween® 20 Sigma-Aldrich, Hamburg 
Xylencyanol Sigma-Aldrich, Hamburg 
 
 
2.2 Material and Kits  
  
Blotting paper GB003 Schleicher & Schuell, Dassel 
Coverslips Menzel-Gläser, Braunschweig 
CryotubeTM Nunc, Wiesbaden 
Electroporation cuvettes 2mm  Peqlab, Erlangen 
Endofree® Plasmid Maxi kit (10)  Qiagen, Hilden 
Eppendorf tubes Eppendorf, Hamburg 
Filter 0.22µm Millipore, Schwalbach 
High-Prime-Kit Roche, Mannheim 
Hybond-N nylon membrane GE-Healthcare, München 
HybondTM ECLTM nitrocellulose membrane GE-Healthcare, München 
Hyperfilm ECL high performance GE-Healthcare, München 
Hyperfilm MP  GE-Healthcare, München 
Microcentrifuge tube (1.5 ml)  Eppendorf, Hamburg 
Microscope slides Menzel-Gläser, Braunschweig 
MicroSpin S-200HR columns GE-Healthcare, München 
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MinElute Gel Extraction Kit Qiagen, Hilden; Peqlab, Erlangen 
Mitsubishi thermal papervideo-printer Mitsubishi, Hatfield, UK 
PCR cleanup kit Qiagen, Hilden 
Plastic ware for cell culture Greiner, Frickenhausen; Nunc, Wiesbaden 
Polypropylene conical tubes Becton Dickinson, Heidelberg 
RNeasy Mini Kit  Qiagen, Hilden 
QiashredderTM columns Qiagen, Hilden 
 
 
2.3 Equipment  
 
AxioCam HR digital camera Carl Zeiss, Göttingen 
Axioplan 2 Imaging microscope Carl Zeiss, Göttingen 
Axiovert 200M microscope Carl Zeiss, Göttingen 
BioPhotometer 6131 Eppendorf, Hamburg 
Centrifuge 5417 R Eppendorf, Hamburg 
Centrifuge RC5B Plus   Thermo Scientific Kendro, Schwerte 
Dounce tissue grinder set Sigma-Aldrich, Hamburg 
Electroporator (Easyject Prima) Peqlab, Erlangen 
GS Gene LinkerTM UV Chamber BioRad Laboratories, Hercules, USA 
Incubator for cell culture Heraeus Instruments, Hanau 
PCR system 2400  Perkin Elmer, Massachusetts, USA 
Stereomicroscope Leica Microsystems, Wetzlar 
Stratalinker Stratagene, Amsterdam 
Thermomixer 5436 Eppendorf, Hamburg 
 
 
2.4 Software  
  
Openlab 3.08 (Improvision, Coventry, UK) and Leica-TCS 2.61 were used for 
visualizing and photographic documentation of cells. Pictures were processed with 
Openlab Demo 5.01 (Improvision, Coventry, UK) or ImageJ (Wayne Rasband, 
National Institutes of Health, USA) and worked on Microsoft Powerpoint 2004. Mac 
VectorTM 9.0 (Oxford Molecular Group) was used for sequence analysis and primers 
design. Microsoft Office 2004 for Mac (Microsoft Corporation, USA) was used for text 
editing, table calculations and graphic images, Adobe Reader 7.0 (Adobe Systems, 
Mountain View, U.S.A) was used to convert documents into PDF format. 
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2.5 Buffers and Solutions  
  
All buffers and solution were prepared with deionized H2O (ddH2O) or H2O treated 
with diethyl pyrocarbonate (DEPC) when working with RNA. 
 
Buffer A  
(for nuclei preparation) 
 
10 mM  HEPES pH 7.9 
10 mM  KCl 
1.5 mM  MgCl2 
0.5 mM  DTT 
Church Buffer 0.5 M   Sodium Phosphate Buffer pH 7.2 
7 %  SDS 
1 mM   EDTA 
Co-IP Buffer Co-IP Lysis Buffer 
200 mM NaCl 
Co-IP Lysis Buffer 10 mM  Tris/HCl pH 7.4 
1 mM  EDTA 
1 mM  DTT 
2 %  protease inhibitor coctail 
1 mM  Na2MoO4  
1 mM  NaVO3  
0.1 %  SDS 
Co-IP wash buffer 50 mM  Tris/HCl pH 8.0 
200 mM NaCl 
0.1 %  Triton-X100 
1 mM   PMSF 
DEPC-H2O 0.01 % diethyl pyrocarbonate (DEPC) in ddH2O 
mixed well, incubated over night at 37°C and autoclaved 
DNA loading buffer 6x 0.03 %  bromophenolblue 
0.03 % xylencyanol 
10 mM  Tris/HCl pH 7.5               
50 mM  EDTA pH 8.0 
30 %   glycerol  
Doxycycline 1 mg/ml in ddH2O 
stored at 4°C, protected from light; used as 1 µg/ml 
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electrophoresis buffer 10x 30 g   Tris 
144 g   glycine 
1 %   SDS 
Hygromycine 50 mg/ml solution  
stored at 4°C, protected from light; used as 100 µg/ml 
Laemmli loading buffer 2x 100 mM Tris/HCl pH 6.8 
200 mM  DTT 
4 %  SDS 
0.2 %  bromophenolblue 
20 %  glycerol 
5 mM   EDTA 
Luria Bertani Medium  
(LB Medium) 
25 g   Luria Broth Base (Invitrogen) 
1 l dH2O, autoclaved 
MOPS RNA running 
buffer 10x 
2 M   MOPS 
500 mM NaAc 
10 mM  EDTA 
adjusted to pH 7.0, stored at RT protected from light 
paraformaldehyde (PFA) 
3,7 % 
1.85 g   paraformaldehyde  
3.5 ml   ddH2O 
10 µl  10 M KOH 
mixed together in a 50 µl Falcon tube. Boiled water in a 
250 ml-glass bottle and put tube in it with cap loose, 
swirling frequently to mix, for no longer than 5 min. 
added: 20 ml ddH2O and 25 ml 2X PHEM buffer 
stored at 4°C for 1 month 
PBS 80 g  NaCl 
14.4 g   Na2HPO4 
2.4 g   NaH2PO4 
2 g  KCl 
pH 7.4, adjusted to 1l and autoclaved 
PHEM buffer 2x 18.14 g PIPES 
6.5 g  HEPES 
3.8 g  EGTA 
0.99 g  MgSO4 
pH 7.0 with 10 M KOH, adjusted to 500 ml with ddH2O, 
filtered and stored in frozen aliquots or at 4°C 
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Ponceau S solution  
 
0.1%   Ponceau S 
5 %   acetic acid 
protease inhibitor coctail 1 tablet in 1 ml H2O 
Puromycine 10 mg/ml in ddH2O 
stored in aliquots at -20°C, used as 1 µg/ml 
RNA sample buffer 50 %   formamide 
15 %   formaldehyde (37%) 
1x   MOPS pH 7.0               
0.1 %  bromophenolblue 
10 µg/ml  ethidiumbromide 
S1 solution 0.25 M  sucrose 
10 mM  MgCl2 
S2 solution 0.35 M  sucrose 
0.5 mM MgCl2 
S3 solution 0.88 M  sucrose 
0.5 mM MgCl2 
SDS 10 % 10 % (w/v)  sodium dodecylsulfate  
SDS running buffer 10x 1.92 M  glycine 
250 mM Tris base 
1 %   SDS 
Sodium phosphate buffer 
pH 7.2 
684 ml  1 M Na2HPO4  
316 ml  1 M NaH2PO4 
pH 7.2 
Sparfloxacine 20 mg/ml in 0.1 N NaOH 
stored at 4°C, protected from light; used as 1 µg/ml 
SSC 20x 3 M  NaCl 
0.3 M  sodium citrate  
pH 7.0, autoclaved 
TBF1 30 mM  potassium acetate 
10 mM  CaCl2 
50 mM  MnCl2 
100 mM  RbCl 
15 %   glycerol 
adjusted to pH 5.8 with 1 M acetic acid and filtered 
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2.6. Culture media 
 
2.6.1 Culture medium for bacteria  
  
Luria Bertani (LB) medium was prepared with H2O and autoclaved. For LB agar 
plates 1.5 % agar was used. In order to select transformed cells ampicilline or 
kanamycine was added to the medium at final concentration of 100 µg/ml and 50 
µg/ml, respectively. LB-agar medium with antibiotic was poured onto petri dishes and 
stored at 4° C. 
TBF2 10 mM  PIPES pH 6.5 
75 mM  CaCl2 
10 mM  RbCl 
15 %   Glycerol 
adjusted to pH 6.5 with 1 M KOH and filtered 
TBS 1x 10 mM  Tris/HCl pH 8.0 
150 mM  NaCl  
TBST washing buffer 1x  
 
1X TBS 
0.1 %   Tween® 20  
TE buffer 10x 
 
100 mM Tris/HCl pH 8.0 
10 mM  EDTA  
Transfer buffer 3 g   Tris  
14.4 g   glycine 
20 %   methanol  
Transfer buffer 1X   Western blot buffer 
20 %  methanol 
Tris/SDS pH 6.8 250 mM Tris base 
0.2 %  SDS 
adjusted to pH 6.8 with HCl 
Tris/SDS pH 8.8 750 mM Tris base 
0.2 %  SDS 
adjusted to pH 8.8 with HCl 
Western blot buffer 10x 1.92 M  glycine 
250 mM Tris base 
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2.6.2 Cell culture medium  
  
All cell culture media and solutions were handled under sterile conditions and stored 
at 4°C. Dulbecco ́s Modified Eagle medium (DMEM), was supplemented with 10% 
(v/v) fetal calf serum (FCS), penicillin/streptomycin and L-Glutamine. For 
transfections of mammalian cells OptiMEM (Invitrogen) was used. For cell 
preservation, cells were resuspended in 90% FCS and 10% DMSO. 
 
 
2.7 Cell lines and strains 
 
2.7.1. Bacterial strains 
 
Strain Genotype 
DH10B 
(Invitrogen) 
F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 
endA1 araD139 ∆(ara, leu)7697 galU galK λ- rpsL nupG  
XL1-BLUE 
(Stratagene)  
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB 
laclqZDM15 Tn10 (Tetr) 
 
2.7.2. Mammalian cell lines 
 
Name Cell type/origin 
HeLa human cervix carcinoma 
U2OS human osteogenic sarcoma, p53 wild type 
HepG2 human , p53 wild type 
T98G human glioblastoma multiform 
TGR-1 rat, fibroblast 
HCT-/- p53, HCT+/+ p53 * human colon carcinoma p53 null or wild type 
* kindly gift from Dr. Harald Gerhard (AGV Apoposis, Helmholtz Centre Munich) 
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2.8. Plasmids 
 
Name short description 
pUC18-HA * provides a COOH-terminal HA tag  
pSfiExpress-HA * provides a COOH-terminal HA tag  
pRTS-1* Doxycycline inducuble bidirectional promoter controls simultaneously 
the expression of both eGFP and the gene of interest (Bornkamm et al., 
2005) 
pBiFC-YN (1-154) ‡ provides a N-terminal FLAG tag and the first 154 amino acids from 
YFP to the C-terminus, (Hu et al., 2002)  
pBiFC-YC (155-238) ‡ provides a N-terminal HA tag and the amino acids 155 to 238 from C-
terminus of YFP (Hu et al., 2002) 
p80-GFP* provides p80 (coilin)-GFP tagged for immunofluorescence 
pEGFP-C1** provides N-terminal GFP  
pEGFP-N1* provides C-terminal GFP  
‡ provided by Dr. Andreas Thomae, Helmholtz Centre Munich 
* provided by Dr. Michael Hölzel, Helmholtz Centre Munich 
**provided by Dr. Rob Chapman, Helmholtz Centre Munich 
 
 
2.9. Oligonucleotides 
 
All nucleotides were synthesized by Metabion at the concentration of 100 pmol/µl.  
 
Oligonucleotide Sequence 5’-3’ Tm °C 
BglII fwd GAT CAG ATC TAT GGG ACA GTC AGG 54 
Ppan Seq middle CAC CAT CAA GCG CTG CCT CCT C 65.8 
Ppan-Sfimut-fwd2 Pho-CAG GCT CAG CAG GCT CAG AAT G 65.9 
Ppan-Sfimut-rev3 Pho-CCT CTG CGC CTT CAG CCG CAG 69.1 
Pp-start GCC ACC ATG GGA CAG TCA GGG 67.2 
Pp-end GGC CAC TCT CTT CCC TGG G 63.8 
Pp-delN-for GCC ACC ATG TCG TTC GTG TTC AC 66.4 
Pp-delBrixA-for GTG AAC CTG AAC ACC ATC AAG CGC 66.9 
Pp-delBrixA-rev GTG CGG GTT CGC GGC ATA G 63.8 
Pp-delBrixB-for AGC AAG ACG GAG GAG GAG CTG C 67.7 
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Oligonucelotides (continued) 
Oligonucleotide Sequence 5’-3’ Tm °C 
Pp-delBrixB-rev GTG CAC GTT GAT GGA GGG GAA C 65.9 
Pp-delcoc-for CTG GAG GGC ATG AAG AAG GCA C 65.9 
Pp-delcoc-rev CTT GCT CAC AAA ACT GTG GAA CAT CAC 66.8 
Pp-delC-rev GCT CTT CTT TCT GTG GGC CTC C 65.9 
pRTS_Sfi+55bp rev AAT CAA GGG TCC CCA AAC TC 55 
SalI rev GCA AGT CGA CGG CCA CTC TCT 54 
YN EcoRV fwd ATC ATA TCG GTA CCA GTC GAC TCT AGA GGA TCC 66.3 
YN EcoRV rev ATC TAT CGA TGA ATT CGC GGC CG 62.2 
YC EcoRV fwd GAT ATC TCT CGA GGT ACC GCG GCC 67.1 
YC EcoRV rev GGT CGA CCG AAT TCG GGC C 66.7 
YN col fwd CTT GCG GCC GCG AAT TC 60.9 
YC col fwd CAT GTA CCC ATA CGA TGT TCC AG 59.1 
YN 1094 (rev) CGT CCA GCT CGA CCA GGA TG 70.5 
YC781 (fwd) GTG TTA CTT CTG CTC TAA AAG CTG CG 66.8 
YC998 (rev) TTC ACC TTG ATG CCG TTC 62.3 
 
 
2.10 Antibodies  
 
2.10.1 Primary antibodies 
 
  
Name (alphabetically) Company species Dilution 
α-Bop1 (6H11) Helmholtz-Centre, Munich* rat 1:10 
α-fibrillarin  Abcam ab5821, Cambridge rabbit 1:1.000  
α-FLAG (M2) Sigma-Aldrich F1804, Hamburg  mouse 1:5.000 (WB) 
1:1.000 (IF) 
α-HA (3F10) Roche, Mannheim rat 1:1.000  
α-HA (12CA5) Roche, Mannheim mouse 1:1.000  
α-Hdm2 (D-12) Santa Cruz Biotechnology, 
Heidelberg 
mouse 1:1.000  
α-Hdm2 (SMP-14) Santa Cruz Biotechnology, 
Heidelberg 
mouse 1:1.000  
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primary antibodies (continued) 
Name (alphabetically) Company species Dilution 
α-hRrp6 
(PM-Scl, Exosc10) 
Sigma-Aldrich P4124, Hamburg rabbit 1:1.000  
α-nucleophosmin (FC-6) Sigma-Aldrich B0556, Hamburg mouse 1:12.000 (WB) 
1:1.000 (IF) 
α-p53 (DO-1) Santa Cruz Biotechnology, 
Heidelberg 
mouse 1:2.000 (WB) 
1:200 (IF) 
α-Pes1 (8E9) Helmholtz-Centre, Munich* rat 1:10 (WB) 
1:100 (IF) 
α-PML (PG-M3) sc-966 Santa Cruz Biotechnology, 
Heidelberg  
mouse 1:1.000  
α-Ppan (1C3) Helmholtz-Centre Munich* rat 1:500 
α-splicing factor sc-35  Sigma S4045 mouse 1:1.000  
α-alpha-tubulin (DM1A) Sigma T6199 mouse 1:40.000 
α-WDR12 (1B8) Helmholtz-Centre Munich* rat 1:10 
WB: Western blot, IF: Immunofluorescence 
*Service unit monoclonal antibodies, Helmholtz-Centre Munich-mAb 
 
2.10.2 Secondary antibodies 
 
Name Company species Dilution 
α-rat HRP Dianova, 112-035-062, Hamburg goat 1:5.000 
α-mouse HRP Promega W402B, Mannheim goat 1:5.000 
α-rabbit HRP Promega W401B, Mannheim goat 1:5.000 
α-rat Alexa 488 Invitrogen, Karlsruhe  goat 1:400 
α-mouse Alexa 488 Invitrogen, Karlsruhe  goat 1:400 
α-rat Cy3 Dianova, 112-165-167, Hamburg goat 1:300 
α-mouse Cy3 Dianova, 115-165-062, Hamburg goat 1:300 
α-mouse Cy5 Dianova, 115-175-166, Hamburg goat 1:500 
α-rabbit Cy3  Dianova, 111-165-045, Hamburg mouse 1:300 
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Methods 
 
2.11 Working with DNA  
  
2.11.1 Mini preparation of plasmid DNA (miniprep)  
 
For mini preparation buffers of the Qiagen plasmid maxi kit were used. First, single E. 
coli colonies were inoculated in 2 ml of LB medium plus selective antibiotics and 
incubated overnight with vigorous shaking at 37°C. Each culture was centrifuged for 
10 min at 10.000 rpm and the supernatant removed. The bacterial pellet was 
resuspended in 300 µl of P1 resuspension buffer and cells were lysed by adding 300 
µl P2 lysis buffer followed by 5 min incubation at RT. 300 µl of P3 neutralization 
buffer was added to the lysate, gently mixed and the reaction was centrifuged for 10 
min at 14.000 rpm. The supernatant containing the plasmid DNA was transferred to a 
fresh 1.5ml tube. DNA was purified by precipitation with 0.7 vol of isopropanol 
followed by 10 min incubation on ice and 30 min centrifugation at 4°C (14.000 rpm). 
The DNA pellet was washed with 1 ml 70 % ethanol (10 min; 14.000 rpm, 4°C), air 
dried and dissolved in 30 µl ddH2O. DNA was stored at 4°C.  
 
2.11.2 Maxi preparation of plasmid DNA (maxiprep)  
 
For maxi preparation of DNA the Qiagen plasmid maxi kit was used. The bacterial 
cells of a 200 ml-overnight culture were harvested by centrifugation at 3.000 rpm for 
10 min at 4°C. The pellet was resuspended with 10 ml P1 buffer and the instructions 
of the kit were followed. The DNA was resuspended in buffer TE and stored at 4°C.  
 
2.11.3 Determination of nucleic acid concentration 
 
Concentration of DNA and RNA was determined in an UV spectrophotometer 
(BioPhotometer 6131, Eppendorf, Hamburg). 2 µl of sample were diluted in 198 µl 
H2O and measured by absorption at 260 nm and 280 nm. The concentration was 
calculated according to the ratio A260/A280. 1 A260 unit of double-stranded DNA = 50 
µg/ml and of RNA = 40 µg/ml.   
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2.11.4 DNA digestion 
 
For preparative restrictions 4 µg plasmid-DNA were digested with 10 U of the 
appropriate enzyme in recommended buffer and optimal temperature in a volume of 
20 µl. Reactions were incubated for 2 hours to overnight. For control restrictions 1 µg 
plasmid DNA or 10 µl from a mini-prepared DNA were digested with 5-10 U enzyme 
in 20 µl volume for 1-2 hours. 
 
2.11.5 Polymerase Chain Reaction (PCR)  
 
2.11.5.1 PCR for cloning 
 
The human ppan sequence NM_020230 was used to design primers flanking the 
ppan open reading frame. A 1419 bp ppan cDNA fragment was amplified by RT-PCR 
from EREB 2.5 RNA (gift from Dr. M. Schlee) using previously phosphorylated ppan 
start and ppan end primer pair. To phosphorylate the primers 2 µl of each primer (10 
µM) was incubated with 1 µl ligase buffer and 1 µl T4-Polynucleotidkinase in 10 µl 
reaction volume at 37°C for one hour. The mixture containing phosphorylated primers 
was used for the PCR reaction with the Platinum Pfx Polymerase under following 
conditions: 
 
10x Pfx amplification buffer 5 µl 
50 mM MgSO4 1 µl 
dNTP mixture (10 mM each) 1.5 µl 
primer mix  10 µl 
cDNA (10 pmol/µl) 3 µl 
10X PCRx Enhancer Solution 1 µl 
Platinum Pfx DNA Polymerase 1 µl 
autoclaved, distilled water 27.5 µl 
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PCR program 
94°C (denaturation) 2 min  
94°C (denaturation) 
58°C (annealing) 
68°C (extension) 
15 sec 
30 sec 
2 min 
 
30x 
72°C (final extension) 10 min  
 
2.11.5.2 PCR for site directed mutagenesis  
 
Site directed mutagenesis was used to make point mutations and delete DNA 
sequences coding for protein domains. In addition the internal SfiI restriction site of 
ppan was silently mutated (from GCC to GCT). 
 
10x Pfu buffer 5 µl 
dNTP mixture (10 µM each) 1.5 µl 
primer mix (10 µM each) 3 µl 
pUC18-Ppan HA 10 ng/µl 1 µl 
Pfu Polymerase 1 µl 
autoclaved, distilled water 38.5 µl 
  
PCR program 
94°C 2 min  
94°C 
63°C 
72°C 
30 sec 
30 sec 
8.5 min 
 
25x 
72°C 10 min  
 
The template DNA was eliminated by over night enzymatic digestion with DpnI, a 
restriction enzyme, which cleaves only bacterial methylated DNA (by Dam 
methylase). The mutated plasmid is preserved because it was generated in vitro and 
is unmethylated as a result. 
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2.11.5.3 PCR for controlling (colony PCR) 
 
Colony PCR was performed to investigate the existence and orientation of the cloned 
sequences in newly generated plasmids.  Bacterial colonies were picked with sterile 
pipette tips and each released in 20 µl of reaction mix. In parallel a copy of the colony 
was saved on a new agar plate with appropriate antibiotic and incubated at 37°C.  
The reaction mix for PCR contained for one reaction: 
 
10X Taq Polymerase Buffer 2 µl 
50 mM MgCl2  1 µl 
dNTP mix (each 10 µM) 0.4 µl 
foreward primer 0.05 µl 
reverse primer 0.05 µl 
Taq polymerase (5 u/µl) 0.2 µl 
autoclaved, distilled water 16.3 µl 
 
PCR program 
94°C  10 min  
94°C  
Tm-3°C  
72°C  
15 sec 
30 sec 
1 kb/min 
 
30x 
72°C  10 min  
 
2.11.6 DNA Ligation 
 
For ligating restricted fragments both vector and insert were cut to have compatible 
ends. Prior to ligation blunt end cut vectors were dephosphorylated to avoid 
undesired religation. For this, appropriate amount of the vector was incubated with 1 
µl Calf Intestine Alcaline Phosphatase (CIAP) with 1 µl CIAP buffer in 10 µl reaction 
volume at 37°C for 1 hour. The CIAP was then removed using the PCR cleanup kit 
(Qiagen). Vector and insert were used at proportion 3:1 in the ligation reaction in a 10 
µl volume. Blunt end ligations of PCR products were performed in presence of 5% 
PEG-6000. The reactions were incubated at 16°C over night. 
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2.11.7 Transformation of E.coli  
 
Chemically competent cells (100 µl aliquot) were mixed with 1 µl plasmid DNA (50-
100 ng) or 10 µl ligation reaction. Reaction was incubated for 30 min on ice, heat 
shocked for 45 sec at 42°C and placed on ice for 2 more min. 900 µl LB medium was 
added to the reaction, which was incubated for 60 min shaking at 37°C. Cells were 
subsequently plated onto LB agar containing appropriate selective antibiotics. Plates 
were incubated overnight at 37°C.  
Alternatively, electrocompetent cells (40 µl aliquot) were mixed with 1 µl plasmid DNA 
(50-100 ng) or 5 µl ligation reaction (the ligase was prior inactivated at 70°C for 10 
min) incubated for 1 min on ice and transferred to a previously cooled electroporation 
cuvette. The cuvette was placed in the electroporator and cells were electroporated 
at 1.8 kV. After electroporation, 900 µl LB medium was immediately added to the 
cells, the suspension was transferred to a fresh 15 ml tube and incubated for 1 hr 
with vigorous shaking at 37°C. Cells were harvested by brief centrifugation (15 sec, 
at 14. 000 rpm), resuspended in 200 µl LB medium and plated onto LB agar plates 
containing the appropriate selective antibiotic. Plates were incubated overnight at 
37°C. 
 
2.11.8 Preparation of chemocompetent cells   
 
An overnight culture of E.coli strain DH10b was diluted 1:100 in LB medium 
supplemented with 20 mM MgSO4 and incubated at 37°C until an OD600 of 0.4-0.6 
was reached. The bacterial cells were centrifuged for 5 min at 4.500 rpm and 4°C 
and washed in 20% of the primary culture volume icecold TBF1. Afterwards the cells 
were resuspended in 2% of the primary culture volume icecold TBF2 and incubated 
on ice for 60 min. Cells were split in 100 µl-aliquots, quickly frozen in liquid nitrogen 
and stored at -80°C.  
 
2.11.9 Preparation of electrocompetent cells 
 
An overnight culture of E.coli XL1-blue was diluted into 400 ml LB medium and 
incubated for approx. 2-3 hours until culture had reached an OD600 of 0.5-0.6. 
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Bacterial suspension was cooled on ice and cells were harvested by centrifugation 
for 5 min at 4.500 rpm and 4°C. Pelleted cells were washed twice with 400 ml ice 
cold 10% glycerol, twice with 40 ml ice cold 10 % glycerol and finally resuspended in 
800 µl of the same solution. Cells were aliquoted (40 µl vol) in sterile 1.5 ml tubes, 
quickly frozen in liquid nitrogen and stored at -80°C.  
 
2.11.10 DNA electrophoresis and isolation of fragments 
 
Agarose gels from 0.8 % to 2 %, dependent on the DNA fragment, were prepared by 
boiling the desired amount of agarose in 0.5x TAE in the microwave. For visualizing 
DNA in the gel, 1 µg/ml ethidium bromide was added. If desired, DNA fragments 
were cut out of the gel under UV light (312 nm) with a sterile scalpel and transferred 
to a sterile 1.5 ml tube. Gel extraction was performed with the MiniElute Gel 
Extraction Kit (Qiagen). 
 
2.11.11 Cloning into pUC18 HA 
 
The RT-PCR product described under 3.1.5.1 was cloned blunt end into the EcoRV site of 
the pUC18-HA vector (gift from Dr. M. Hölzel) in order to get a C-terminal fused HA-tag 
sequence and fully sequenced with primers M13 for and M13 rev (provided by 
Sequiserve).  
 
2.11.12 Cloning into pRTS 
 
Cloning in this vector was useful for stable transfections of human cells (Bornkamm et al., 
2005). First of all, ppan was mutated by inverse PCR using primers Sfi mut fwd and Sfi 
mut rev in plasmid pUC18-PpanHA in order to eliminate the internal SfiI restriction site, 
considering the human codon usage. PpanHA in pUC18-PpanHA was digested with SfiI 
and cloned between the SfiI sites of the vector pRTS-SVH-GL, replacing the gene for 
Luciferase resulting in pRTS-PpanHA (Fig. 6). The correct direction of cloned ppan was 
confirmed by bacterial colony PCR, using primers pRTS_Sfi+55bp rev and Pp-delcoc-for 
and restriction enzyme analysis after isolation of the plasmid DNA. pRTS is carrying genes 
coding for ampicilline resistance to select positive bacterial clones and hygromycine 
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resistance to select positive human cell clones. Production of PpanHA in stably transfected 
cells was tested by Western blot analysis.  
 
 
 
 
 
 
 
 
Fig. 6. Model of pRTS-PpanHA (simplified). The 
bidirectional promoter (in blue) controls simultaneously 
the expression of both egfp (in green) and ppan (in 
red) and is activated by doxycycline. The plasmid 
carries a hygromycine resistance gene for selection of 
stable mammalian cells and an ampicilline resistance 
cassette for selection of transformed bacteria. 
 
 
2.11.13 Cloning into pSfiExpress HA 
 
Cloning in this vector is useful for transient transfections of human cells, because the 
expression of the gene of interest is controlled by the cytomegaly virus (CMV) promoter, 
which is constitutively active in mammalian cells. The ppan cDNA fragment (see under 
“cloning into vector pUC18 PpanHA”) was cloned blunt end in the EcoRV digested 
pSfiExpressHA vector (gift from Dr. Michael Hölzel), which was primarily 
dephosposphorylated. The right direction of cloned ppan in ligated plasmids was tested by 
bacterial colony PCR and confirmed by sequencing using primers CMV profor (provided by 
Sequiserve) and PP-delBrixB-for. pSfiExpress carries a gene coding for kanamycine 
resistance in E.coli. 
 
2.11.14 Cloning into pEGFP-N1 
 
Prior having a functional Ppan specific antibody, the subcellular localization of Ppan was 
monitored with a Ppan-GFP fusion protein. A plasmid expressing the green fluorescent 
protein (gfp) as a C-terminal fusion to ppan under control of the CMV promoter was 
constructed. For this, full-length ppan was cut out from plasmid pUC18-PpanHA with SacI 
and BstEII restriction enzymes and cloned in frame with the gene coding for green 
pRTS-PpanHA 
18208bp 
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fluorescent protein into the pEGFP-N1 vector (gift from Dr. Michael Hölzel). The ppan-gfp 
gene fusion of the plasmid was fully sequenced with primers CMV profor (provided by 
Sequiserve) and PP-delBrixB-for. For generation of a PpanΔσ70-GFP fusion, ppanΔσ70 
was cut out from plasmid pUC18- PpanΔσ70HA with SacI and BstEII restriction enzymes 
and cloned in frame with gfp as already described for ppan. 
 
2.11.15 Cloning into pEGFP-C1 
 
For construction of a GFP-Ppan fusion protein, the primers BglII fwd and SalI rev were 
used to amplify ppan with the restriction sites BglII and SalI on the 5’ and 3’ end 
respectively. After digestion of the vector pEGFP-C1 (gift from Dr. Rob Chapman, 
Helmholtz Centre Munich) with the appropriate enzymes and the following ligation with the 
BglII-ppan-SalI fragment, the newly formed plasmids were tested in colony PCR reactions. 
A pEGFP-C1-Ppan plasmid was sequenced with primers EGFP-Cfor and SV40-pArev 
(provided by Sequiserve). 
 
2.11.16 Cloning into vectors for BiFC analysis 
 
Cloning in the vectors pBiFC-YN(1-154) and pBiFC-YC(155-238) (provided by Dr. Tom 
Kerppola, Howard Hughes Medical Institute, University of Michigan, USA and gift from Dr. 
Andreas Thomae, Helmholtz Centre, Munich) was useful for performing BiFC analysis in 
human cells. The principle of BiFC assay function is described in the results of this thesis. 
A scheme of pBiFC plasmids is shown in figure 7. 
 
 
 
 
Fig. 7. Plasmids used for BiFC. Models of 
plasmids YN (1-154) (pBiFC-YN(1-154)) and 
YC (155-238) (pBiFC-YC(155-238)). 
 
2.11.17 Cloning into vector pBiFC-YN(1-154)  
 
First of all, the original pBiFC-YN155 vector was mutated at the multiple cloning site with 
inverse PCR using primers YN EcoRV fwd and YN EcoRV rev in order to get a new 
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EcoRV (GAT ATC) site (Fig. 8). This new EcoRV restriction site in pBiFC-YN(1-154)* 
allows in frame blunt end ligation of any cDNA sequence starting with ATG and ending just 
prior to the stop codon, because following yfp should be successfully transcribed. The old 
EcoRV site was destroyed by the PCR reaction.  
 
 
 
Fig. 8. DNA sequence of the multiple cloning site of the original plasmid pBiFC-YN(1-154). 
Mutagenesis with primers YN EcoRV fwd (ATC ATA..) and YN EcoRV rev resulting in substitution 
of CTG (in red boxes) with ATC by forward primer and formation of a new EcoRV site (GAT ATC) 
for in-frame cloning of every cDNA starting with ATG and ending one triplet just before stop codon 
to allow following yfp to be translated. The old EcoRV site is underlined in red. 
 
The ppan cDNA fragment (see under “cloning into vector pUC18 PpanHA”) was cloned 
blunt end into the EcoRV digested pBiFC-YN(1-154)* vector which was primarily 
dephosphorylated. Ligated new plasmids were controlled by bacterial colony PCR to 
confirm the successful cloning and simultaneously the direction of cloned ppan with 
primers YN col fwd and Pp-delcoc-rev. A plasmid carrying ppan in the right direction was 
sequenced with primers CMV profor (provided by Sequiserve) and YN 1094 (rev) and 
used for BiFC analysis. For the sake of simplicity this plasmid is decribed as YN Ppan in 
this work.  
 
2.11.18 Cloning into vector pBiFC-YC(155-238)  
 
Cloning in this vector was useful for performing BiFC analysis in human cells. As done with 
the original pBiFC-YN155 vector, the original pBiFC-YC(155-238) vector was mutated at 
the multiple cloning site with inverse PCR using primers YC EcoRV fwd and YC EcoRV 
rev in order to generate a new EcoRV (GAT ATC) site (Fig. 9). This new EcoRV restriction 
site in pBiFC-YC(155-238)* allows, similar to pBiFC-YN(1-154)*, in frame blunt end ligation 
of any cDNA sequence starting with ATG and ending just prior to the stop codon, to allow 
the carboxy-terminal part of yfp to be successfully translated.  
old EcoRV 
site 
FLAG tag 
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Fig. 9. DNA sequence of multiple cloning site of the original plasmid pBiFC-YC(155-238). 
Mutagenesis with primers YC EcoRV fwd (GAT ATC..) and YC EcoRV rev resulting in substitution 
of GAG (in red box) with GAT by forward primer and formation of a new EcoRV site (GAT ATC) for 
in-frame cloning of every cDNA starting with ATG and ending one triplet just before stop codon to 
allow following yfp to be translated.  
 
The ppan cDNA fragment (see under “cloning into vector pUC18 PpanHA”) was cloned 
blunt end into the EcoRV digested pBiFC-YC(155-238)* as described for pBiFC-YN(1-
154)*. The colony PCR was performed using the primers YC col fwd and Pp-delcoc-rev.  
The new plasmid was sequenced with primers YC781 (fwd) and YC998 (rev) and used for 
BiFC analysis.  The plasmid coding for the Ppan-YFP fusion in pBiFC-YC(155-238)* is 
named YC Ppan in this work.  
 
2.11.19  Cloning of pes1, bop1, wdr12 and hdm2 into vector pBiFC-YC155  
 
cDNA fragments of pes1 (NM_ 014303.2), bop1 (NM_013481.1), wdr12 (NM_018256.2) 
and hdm2 (NM_002392.2) were amplified from total cDNA of U2OS cells. Cloning into the 
pBiFC-YC(155-238)* plasmid was similar to that described for YC Ppan (amplification PCR 
and cloning were done by Dr. Michaela Rohrmoser, Helmholtz Centre Munich). Resulting 
plasmids were named for simplicity YC Pes1, YC Bop1, YC WDR12 and YC Hdm2. 
 
2.11.20 Mutagenesis of human ppan 
 
The mutagenesis of ppan was done by inverse PCR in pUC18-Ppan HA with specific 
flanking primers as indicated at Tab. 3. The genes encoding the new truncated forms of 
Ppan were subcloned into pSfiExpress and pRTS-SVH-GL, as already described for ppan. 
 
yfp  
(for aa155- 238 
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Tab. 3. Mutagenesis of ppan for generation of new Ppan forms. 
ppan mutagenesis 
(deletion of nucleotides) 
Primers for mutagenesis of 
cDNA 
new Ppan forms  
(deletion of amino acids) 
Δ 1-87 Pp-delN-for  
Pp-end 
Ppan ΔN (1-29) 
Δ 511-903 Pp-delBrixB-for 
Pp-delBrixB-rev 
Ppan Δσ70 (172-301) 
Δ 91-513 Pp-delBrixA-for 
Pp-delBrixA-rev 
Ppan ΔBrixA (31-171) 
Δ 904-1041 Pp-delcoc-for 
Pp-delcoc-rev 
Ppan Δcoc (304-342) 
Δ 1019-1419 Pp-start  
Pp-delC-rev  
Ppan ΔC (343-473) 
 
 
2.12 Working with RNA 
 
2.12.1 Preparation of RNAse free solutions 
 
For RNAse free water and solutions diethyl pyrocarbonate (DEPC) was added in a 
final concentration of 0.1% and after incubation at 37°C over night, autoclaved.  
 
2.12.2 Isolation of RNA 
 
Total RNA from adherent cell lines was isolated using the RNeasy® Mini Kit 
(Qiagen). For extraction from cultured cell lines, cells of two six-wells of a six-well-
plate were lysed by the addition of 350 µl RLT buffer. For further homogenization, 
samples were passed through a QIAshredder spin column placed in a 2 ml collection 
tube (2 min at 14.000 rpm). 1 vol of 70 % ethanol was added to the homogenized 
lysate and mixed thoroughly by pipetting. The lysate was applied to a RNeasy mini 
column placed in a 2 ml collection tube and centrifuged for 15 sec at 10.000 rpm. The 
flow-through was discarded and the total RNA bound to the column was washed 
once with 700 µl RW1 buffer and twice with 500 µl RPE buffer. The first and second 
centrifugation steps were carried out for 15 sec and the third for 2 min at 10.000 rpm, 
the flow-through was discarded after each washing step. Finally, to elute the RNA 
from the RNeasy column (placed in a fresh 1.5 ml tube), 30 µl RNase-free H2O was 
applied to the column and incubated for 1 min at room temperature. RNA was 
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collected by centrifugation (1 min at 10.000 rpm). RNA concentration was determined 
photometrically. The isolated total RNA was stored at -20°C.   
 
2.12.3 Electrophoresis of RNA and Northern Blot 
 
RNA was electrophoretically separated in 1 % agarose-formaldehyde gels, 
containing 1x MOPS buffer and 6.2 % Formaldehyde. Equal amounts of RNA were 
1:1 mixed with 2x RNA sample buffer and denatured for 10 min at 65°C, with 
subsequent placing on ice. Electrophoresis was performed at 90-120 V and gels 
were photographed. 
For Northern Blot, RNA was blotted on Nylon Membranes (Hybond N+, Amersham) in 
10x SSC Buffer in a capillary transfer system over night. First the RNA gel was 
placed with gel slots down onto a pile of blotting paper GB003 having its ends in a 
10x SSC-containing reservoir. The membrane was soaked in 10x SSC and placed 
blebfree onto the gel and covered by 2 more layers of G003 blotting paper. Free 
surface around the membrane was sealed by Saran transparent foil. An 8 cm-thick 
block of paper towels was placed onto the blotting paper, covered by a leveled 
weight glass to ensure equal distribution of pressure on the blot. Finally, a 500 g 
weight was distributed on the glass plate. Transfer was performed over night at room 
temperature. Next day, after briefly drying the membrane at room temperature, the 
RNA was UV-cross-linked with the Stratalinker (program: auto cross link). 
 
2.12.4 Hybridisation with phospho-labeled probes  
 
For detecting the ppan mRNA expression in T98G cells, a probe for ppan was 
labelled with α32P-dCTP (3.000 Ci/mmol) using the High-Prime-Kit (Roche). Briefly, 1 
µl of 1 pmol/µl SfiI-Fragment of pUC18-PpanHA containing ppan was mixed with 8 µl 
H2O and incubated for 5 min at 95°C with subsequent placing on ice. 4 µl High-Prime 
reaction mixture, 3 µl dATP, dGTP, dTTP mixture (prepared by making a 1+1+1 
mixture of provided solutions) and 5 µl of α32P-dCTP (50 µCi) were added to the 
probe and the reaction was incubated at 37°C for 10 min. 2 µl 0.2M EDTA were 
added and probes were purified with MicroSpin S-200HR columns.  
In order to visualize pre-rRNA precursors probes were used, which are specific for 
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the internal transcribed spacers 1 and 2 (ITS-1). The sequences of the probes were: 
ITS-1  5’-CCT CCG CGC CGG AAC GCG CTA GGT ACC TGG ACG GCG GGG 
GGG CGG ACG-3’ 
ITS-2 5’- GCG GCG GCA AGA GGA GGG CGG ACG CCG CCG GGT CTG 
CGC TTA GGG GGA-3’ 
For the labelling reaction 1 µl of the 10 µM DNA-oligonucleotide was mixed with 2 µl 
H2O and heated at 95°C for 3 min, with subsequent cooling on ice. 1 µl T4 
polynucleotide kinase (PNK), 1 µl PNK buffer A and 5 µl (50 µCi) γ32P-ATP were 
added and the reaction was performed at 37°C for 30 min. After addition of 40 µl H2O 
probes were purified with MicroSpin S-200HR columns. 
For the Northern Blot analysis, the nylon membranes with the cross-linked RNA 
(2.12.3) were prehybridized in hybridization tubes (DNA inwards) in 20 ml Church 
Buffer for 60 min at 65°C. The labelled probes were denatured for 5 min at 95°C, 
cooled in ice and resuspended in 10 ml Church Buffer. Northern blot hybridization 
occurred at 65°C over night in a roller oven.  The next day probes were collected and 
membranes were washed at 65°C for 10 min with 2x SSC/0.1 % SDS and afterwards 
for 10 min with 0.2x SSC/0.5% SDS. Finally membranes were air dried, wrapped in a 
transparent membrane and placed in a x-ray cassette. For film exposure (1-5 days) 
the cassette was kept at -80°C.   
 
2.12.5 Synthesis of cDNA  
 
Total RNA was isolated from U2OS cells grown at 80 % confluency on a 15 cm 
culture dish as described in 2.12.2 2 µl of isolated RNA were incubated with 1 µl 
oligo-dT primer (500 µg/ml), 1 µl dNTP mix (10 mM each) in 10 µl volume at 65°C for 
5 min and subsequent chilled on ice. The RNA mixture was collected by brief 
centrifugation and 4 µl RT-Buffer (5x), 2 µl 0.1 M DTT and 1 µl RNAsin 40 U/µl 
(RNAse Inhibitor) were added, gently mixed and incubated for 2 min at 42°C. For 
reverse transcription 1 µl of Superscript II (Invitrogen) was used. Reaction took place 
at 42°C for 50 min. The enzyme was inactivated at 70°C for 15 min and cDNA was 
kept at -20°C. 1.5 µl of cDNA was used for subsequent PCR reaction.  
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2.12.6 Knock-down with siRNA 
  
H1299 and U2OS were seeded at a density of 200.000 cells in 6-well plates the day 
before transfection. 5 µl of 20 µM control, ppan or hrrp6-specific siRNA were diluted 
in 150 µl OptiMEM (Invitrogen). 150 µl OptiMEM containing 4 µl Oligofectamine 
(Invitrogen) was added and the mixture was incubated for 15 min at room 
temperature. 600 µl OptiMEM was added and applied to cells after aspiration of the 
culture medium. Cells were incubated with the transfection mixture for 5–6 h. The 
following sequences were used (sense):  
control  UUC UCC GAA CGU GUC ACG UdTdT 
ppan (3’UTR)  CUC GGU UUC CUU UCA UAA AdTdT 
 
 
2.13 Working with proteins 
 
2.13.1 Production of a monoclonal antibody directed against  
 human Ppan 
 
A panel of monoclonal antibodies raised against the Ppan protein was generated in 
cooperation with Dr. Elisabeth Kremmer from the Institute of Molecular Immunology, 
Helmholtz Centre Munich. A synthetic peptide identical to the N-terminal tail of Ppan 
with the sequence MGQSGRSRHQKRA was used to immunize rats. Many clones 
were tested for reactivity to endogenous and overproduced Ppan in Western blot 
analysis and immunofluorescence and clone 1C3 was elected for further studies.   
 
2.13.2 Lysis under denaturing conditions 
 
Adherent cells of a 6 well were washed once with PBS and lysed when 80% 
confluent with 50 µl 2x Laemmli loading buffer and collected in 1.5 ml tubes. Lysates 
were boiled for 5 min at 95°C, then sonicated for 15 sec (output 4, duty cycle 50%). 
Lysates were kept at -20°C until use. Just prior use lysates were again boiled for 5 
min at 95°C and spun down for 2 min at 14.000 rpm to precipitate insoluble material. 
5-10µl of lysates were applied to every gel slot. 
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2.13.3 Denaturing Polyacrylamide Gel Electrophoresis (PAGE) 
 
SDS-Polyacrylamide (SDS-PAGE) Gel Electrophoresis was used for separation of 
proteins under denaturing conditions. The concentration of the gels used was 
determined according to the effective range of separation of SDS-PAGE shown 
below:  
 
Acrylamide concentration (%) Linear range of separation (kDa) 
15 12-43 
10 22-68 
8 31-97 
 
For the resolving gel the following components were mixed together:  
 
Components (10 ml) 8 % 10 % 15 % 
30 % Acrylamide mix 2.6 ml 3.3 ml 5 ml 
H2O 2.3 ml 1.6 ml - 
Tris/SDS pH 8.8 5 ml 5 ml 5 ml 
10 % APS 85 µl 85 µl 85 µl 
TEMED 10 µl 10 µl 10 µl 
  
Stacking gel was prepared by mixing the following components: 
 
Components (3.8 ml) stacking gel 4 % 
30 % Acrylamide mix 0.5 ml 
H2O 1.35 ml 
Tris/SDS pH 6.8 1.88 ml 
10 % APS 22.5 µl 
TEMED 5 µl 
 
Proteins were separated at 30 mA. 
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2.13.4 Western Blot 
 
Cellular lysates were electrophoresed on 8-15 % SDS-PAGE gels and transferred to 
a nitrocellulose membrane using the wet system. Membranes were pre-wet in 
transfer buffer. Transfer of protein from the gel to the membrane occurred under 
electric current from the negative to the positive pole at 0.45 A for 1.5 hours. The 
membranes were shortly dried and stained with Ponceau S solution to verify equal 
loading. After extensive washes with TBST, membranes were blocked for non-
specific binding sites with 5 % nonfat dried milk for 0.5 hour at room temperature. 
Immunoblotting was carried out with specific antibodies diluted in 5 % nonfat dried 
milk or 5 % BSA in TBST at optimal concentration. Incubation with primary antibody 
was carried out in most cases overnight at 8°C followed by three 5 min washing 
steps with TBST. Secondary antibodies conjugated with horseradish peroxidase 
(HPR) were used for detection of the primary antibody. Incubation was carried out for 
1 hour at room temperature followed by extensive washing steps as described 
above. Finally, the proteins were detected by incubating the membrane with 
enhanced or super enhanced chemiluminescent reagent for 5 min at room 
temperature. The membrane was then wrapped in foil and placed in a x-ray film 
cassette. Exposition of the film varied between 30 sec and 4 min. 
 
2.13.5 Lysis under native conditions for immunoprecipitations 
 
For every immunoprecipitation reaction adherent cells of two 15 cm cell culture 
dishes were washed once with cold PBS and lysed directly on the plate with each 0.5 
ml Co-IP Lysis Buffer. Cells were released with a cell scraper and placed in a 1.5 ml 
tube for 10 min at room temperature. Lysates were sonicated twice for 15 sec (output 
4, duty cycle 50%) with inbetween 1 min pause on ice and spun down for 15 min at 
14.000 rpm and 4°C to precipitate insoluble material. 50 µl of the lysate were mixed 
with 50 µl 2x Laemmli loading buffer and used as input control.  900 µl of lysates 
were applied to Protein G beads pre-coupled with antibody. For this 25 µl Protein G 
bead slurry (in 20 % ethanol) was washed twice in Co-IP wash buffer at 6.000 rpm 
for 1 min and incubated with 500 µl antibody supernatant or 1 µl of concentrated 
antibodies in 500 µl Co-IP buffer for 1 hour at 8°C on a roller. After 3 washes with Co-
IP wash buffer, beads were incubated with cell lysates overnight at 8°C on a roller. 
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Next day beads were washed 5 times with Co-IP buffer supplemented freshly with 
PMSF and resuspended in 50 µl of Co-IP wash buffer plus 50 µl of 2x Laemmli 
loading buffer. Lysates were kept at -20°C until use. Just prior use they were boiled 
for 5 min at 95°C with subsequent cooling on ice and briefly spun down. 
 
2.13.6 Isolation of nucleoli 
 
Nucleoli of HepG2 cells were prepared according to Andersen et al. (2002). All 
centrifugations steps were done in a HS-4 rotor, Sorvall centrifuge, at 4°C. Briefly, 
cells were plated on ten tissue culture dishes with a diameter of 14 cm until >90% 
confluence. Cells were harvested by trypsinization. The harvested cells were pooled 
into 50 ml Falcon tubes and washed 3 times with ice-cold PBS at 218 g (1.000 rpm). 
After the final PBS wash, cells were resuspended in 5 ml of Buffer A and incubated 
on ice for 5 min. Swallen but not burst cells were observed under the microscope. 
The cell suspension was transferred to a pre-cooled 7 ml Dounce tissue 
homogenizer tissue grinder with pestle B (clearance 0.0008-0.00022 in) and 
homogenized with 10 strokes on ice. Homogenized cells were centrifuged at 218 g 
(1.000 rpm) for 5 min. The pellet was resuspended with 3 ml S1 solution and layered 
carefully over 3 ml of S2 solution, keeping the two layers cleanly separated. After 
centrifugation at 1.430 g (2.700 rpm) for 5 min, the nuclear pellet was resuspended in 
1 ml of S2 solution by pipetting up and down and 50 µl were mixed with 2x Laemmli 
loading buffer for western blot analysis. 2 ml of S2 solution were added and nuclei 
were sonicated on ice for 6 x 10 second bursts (with 10 second intervals between 
each burst) at power setting 4 and output control 50%. Sonicated suspension was 
layered carefully on 3 ml of S3 solution keeping the two layers cleanly separated. 
Probe was then centrifuged at 3.000 g (4.000 rpm) for 10 min. The pellet contained 
the nucleoli, which were washed in 0.5 ml S2 solution and centrifuged at 1.430 g 
(2.700 rpm) for 5 min. Finally the pellet containing purified nucleoli was resolved in 
100 µl S2 solution plus 100 µl 2x Laemmli loading buffer.   
 
2.13.7 Immunofluorescence 
 
For immunofluorescence microscopy experiments approximately 80.000 cells were 
plated on 18 mm round and sterile (90 s, program STR, GS Gene LinkerTM UV 
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Chamber) cover slips in 12 well slots. For staining overproduced proteins 
approximately 50.000 cells were seeded per slip and induced 24 hours with 1 µg/ml 
doxycycline. The cells were washed with PBS, fixed with 3.7% paraformaldehyde for 
5 min at room temperature, washed again with PBS, permeabilized with 0.5 % Triton 
X-100 in PBS for 10 min at room temperature and subsequent blocked in 10 % FBS 
in PBS for at least 30 min at room temperature (alternatively over night at 4°C). 
Primary (and secondary) antibodies were diluted in 1.5 % FBS in PBS and incubated 
from 1 hour (α-HA, α-FLAG) to overnight (antiserum supernatant, α-p53, α-NPM, α-
Fibrillarin) at 8°C in a humidified chamber. Unbound antibody was released with 
three 5 min-washes in 0.1 % Triton X-100 in PBS and cells were incubated with 
species specific secondary antibody, conjugated with Cy3, Cy5 (1:300) or Alexa488 
(1:400) at room temperature for 1 hour in a dark humidified chamber. After three 5 
min-washes in a solution of Triton X-100 0.1 % (in PBS) and DNA was 
counterstained with 0.1 µg/ml DAPI for 2 min. Cells were mounted in Dako mounting 
medium, placed on microscope slides and sealed with nail polish to avoid run dry. 
Microscope slides were kept at 4°C and dark. 
For RNAseA or DNAseI in-cell-digestion experiments, cells were permeabilized with 
0.1% Triton-X-100 in PBS for 15 min at room temperature and incubated with 15 
µg/ml RNAseA or DNAseI (in PBS) for 30 min at 37°C, before they were fixed with 
paraformaldehyde. After the fixation, the protocol described above was used. 
 
2.14 Cell culture 
 
Mammalian cells were cultured in Dulbecco’s modified Eagle Medium supplemented 
with 10% fetal bovine serum and antibiotics at 37°C and 8% CO2. Split ratio varied 
between 1:4 and 1:10. To exclude mycobacterial infections of adherent cells 
sparfloxacine (1 µg/ml) was added to the medium. To avoid bacterial resistance to 
this component, it was used only periodically. For cell preservation, cells were 
resuspended in 90% FBS, 10% DMSO, subsequently freezed at -80°C and for long 
term keeping transferred to liquid nitrogen.  
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2.14.1 Transfection of mammalian cells 
 
Twenty-four hours before transfection, mammalian cells were subcultured and 
seeded in a 6-well plate at the density of 2x105 cells per well. Transfection 
experiments were carried out using 2 µg plasmid DNA and 5 µl of Polyfect (Qiagen) 
in the presence of serum, according to the manufacturer’s instructions. An exception 
was the transfection of HepG2 cells for the BiFC analysis where 0.5 µg plasmid DNA 
was mixed with 1.5 µg pUC18 Ppan HA and complexed by 5 µl of FuGene HD 
transfection reagent (Roche). Briefly, formation of DNA-carrier complexes was 
performed in 100 µl serum-free OptiMEM (Invitrogen). 15 min later 500 µl DMEM was 
added and DNA complexes were dropped carefully to the cells. Selection of cells was 
started with hygromycine (100 µg/ml) or puromycine (1 µg/ml) containing medium 24 
hours after transfection. To obtain stable transfected cells the selective antibiotics 
were applied for at least 10-14 days. 
 
 
2.15 Microscopy 
 
2.15.1 Fluorescence microscope  
 
Cells were observed under an automated Axiovert 200M microscope (Carl Zeiss, 
Jena, Germany) equipped with single-band pass filter sets for visualization of DAPI, 
Texas red (cy3) and Alexa 488 (GFP of FITC) fluorescence. Images were recorded 
using the Openlab 3.08 software (Improvision, Coventry, UK) and processed with 
Openlab Demo (free software) or Image J (version 10.2, (http://rsb.info.nih.gov/ij/)). 
 
2.15.2 Confocal laser scanning microscope 
 
The confocal laser scanning microscope Leica LSCM SP2 with software Leica-TCS 
2.61 was used in order to obtain high-resolution optical images, for BiFC analysis 
and co-localization studies. Images were taken with objective HCX PL APO 63x 1.4 
at 400 Hz scan speed, with an average scan of 4 pictures. The argon laser was set at 
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minimum level. For YFP monitoring of BiFC analysis the Alexa 488 channel (529-560 
nm) and photomultiplier PMT 2 at 750 mV was used. 
Three-dimensional pictures were taken by defining end and start point of scanning 
and 0.25 µm thick sections. The average for each picture was set at 1 and a 
sequential modus with the different laser “between frames” was chosen. 
 
For detection of different stainings following settings were preferred: 
Detection of: Excitation (laser) Emission Laserpower 
DAPI 405 nm (UV) 420-470 nm 50% 
Cy3 (PMT 3) 543 nm (Ar/HeNe) 588-617 nm 40% 
Cy5 (PMT 3) 633 nm (Ar/HeNe) 660-694 nm 40% 
Alexa488 (PMT 2) 488 nm (Ar/HeNe) 529-560 nm 40% 
ITC (interference contrast) 405 nm (UV)  40% 
 
The YFP signal of BiFC analysis was monitored at the Alexa 488 channel (529-560 
nm). The photomultiplier PMT 2 was adjusted to 750 mV. 
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3. Results 
 
3.1  Generation of a Ppan specific monoclonal antibody 
 
Monoclonal antibodies are a key tool for identification and characterization of 
proteins, since they recognize only a single epitope of interest. A synthetic peptide 
with the sequence MGQSGRSRHQKRA, corresponding to amino acids 1-13 of the 
N-terminus of Ppan, was used to immunize rats (E. Kremmer, Helmholtz Centre 
Munich). Several hybridoma supernatants were tested in Western blot analysis. 
Monoclonal antibodies of hybridoma clone 1C3 detected the endogenous Ppan 
protein (approx. 62 kDa) in U2OS cells. In cells transfected with a specific small 
interfering RNA (siRNA) for ppan, the signal intensity of the Ppan protein decreased 
significantly, supporting the specificity of the antibody (Fig. 10a). U2OS cells were 
also stably transfected with an expression vector for Ppan, pRTS-Ppan. Antibody 
1C3 recognized the overexpressed protein with a molecular weight of about 64 kDa 
(Fig. 10b). The recombinant Ppan has additionally a C-terminally fused HA-tag, 
which explains the slower migration in polyacrylamid gels. 
 
 
Fig. 10. The Ppan antibody produced by hybridoma clone 1C3 recognizes specifically 
Ppan. (a) U2OS cells were transfected with control- or ppan-specific siRNA. (b) Stably 
transfected U2OS cells with pRTS-Ppan were treated with 1 µg/ml doxycycline to induce the 
expression of PpanHA for 24 hours. Total cell lysates were analysed by Western blot using 
the Ppan-specific antibody 1C3. Tubulin was used as loading control. 
 
The antibody was only stable for approximately two months at 4°C and therefore this 
work was done with several charges of freshly made hybridoma supernatant, which 
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differed in antibody titer. The antibody was used always in excess and incubated for 
at least 48 hours with antigen to allow reproducible results. 
 
 
3.2 Expression and localization of Ppan 
 
Expression of ppan 
 
Normally, cells require growth factors for proliferation in culture. The fetal calf serum 
(FCS) is usually provided as a growth factor supplier in the medium of cultured cells. 
In the absence of serum many cells entry a non-dividing state, the G0 phase, which is 
characterized by low metabolic activity. The addition of FCS induces the proliferation 
of cultured cells and is accompanied by changes in gene expression (Iyer et al., 
1999). The cellular response to serum involves the induction of genes for 
transcription factors, like c-Myc, and reduced expression of transcription regulators 
involved in maintaining the cells in the G0 phase. Since ppan has been described as 
a target gene of the transcription factor c-Myc, its response to growth factor 
stimulation was studied. The human glioblastoma T98G cell line can be synchronized 
by serum starvation without activation of apoptotic pathways. Serum deprived T98G 
cells were incubated with medium containing FCS and the total RNA was isolated at 
different time points following restimulation. Northern blot analysis with a ppan 
specific probe showed an induction of ppan expression four hours after restimulation 
(Fig. 11). The hybridization with the ppan specific probe revealed a single detectable 
transcript of approximately 1.4 kb.  
 
 
 
Fig. 11. Expression of ppan 
increases in restimulated T98G 
cells after serum starvation. 
T98G cells were serum-starved 
for seventy-two hours and 
restimulated in medium containing 
fetal calf serum. Total RNA was 
isolated at indicated time points. 
Northern blot analysis was 
performed with a specific probe 
for ppan. 
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Thus, the expression of the ppan gene is associated with proliferation of T98G cells.  
 
The expression of ppan was studied in a panel of different cell lines. Whole protein 
lysates of a proliferating lung cancer cell line (H1299), a cervical adenocarcinoma 
cancer cell line (HeLa), a human leukemic cell line (J6), Burkitt’s lymphoma cell lines 
(Mutu (-), Mutu I and III, EBV 1.25, Raji, BL60, BL70, Namalwa, CHEP, ww2, DG-75 
and Akata) and a B-lymphoblastoid cell line (721) were analyzed by Western blot 
analysis (Fig. 12) 
 
 
Fig. 12. Expression of Ppan protein in different proliferating cell types. Western blot 
analysis of proteins from distinct cancer cell lines using the specific Ppan antibody. Tubulin 
was used as a loading control. 
 
The Ppan protein was expressed at comparable levels in all studied cell lines. Only 
the BL70 cell line showed reduced Ppan protein levels, when comparing with the 
levels of the other cell lines and the loading control tubulin. Furthermore, the antibody 
against Ppan recognized an additional slower migrating form in the cell lines H1299, 
HeLa, 721 and EBV 1.25. This could indicate a modification of the protein or the 
existence of an isoform of Ppan. In conclusion, Ppan is expressed in a broad range 
of cells, probably in a proliferation associated manner. 
 
 
Localization of Ppan 
 
The yeast homologue of Ppan, Ssf1, localizes to nucleoli (Kim and Hirsch, 1998) and 
proteomic analysis of the human nucleolus revealed that human Ppan is a 
component of purified nucleoli (Andersen et al., 2002). In order to study the cellular 
distribution of Ppan, the human hepatocellular carcinoma cell line HepG2 was used 
for the immunostaining, because it is very suitable for microscopic imaging due to its 
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large nuclei and nucleoli. In asynchronously growing HepG2 cells, Ppan localized in 
all cells at a first glance nuclear (Fig. 13). In the majority of the cells Ppan stained 
more strongly the nucleoli, whereas the nucleolar protein Pes1 localized in all cells 
predominantly nucleolar. To quantify the nucleolar localization more precisely, two 
hundred cells were carefully examined for localization of Ppan or Pes1. The 
percentage of cells showing a protruding nucleolar staining of Ppan was found to be 
77 %. All cells showed a predominant nucleolar staining of Pes1. 
 
 
Fig. 13. Immunofluorescence analysis of endogenous Ppan and Pes1. An asynchronous 
culture of HepG2 cells was fixed with paraformaldehyde and incubated with specific 
antibodies for Ppan (1C3) and Pes1 (8E9). DNA was counterstained with DAPI. 
 
 
To confirm the cellular localization of Ppan, two fusion proteins with the green 
fluorescent protein (GFP) at the N- or C-terminus of Ppan (GFP-Ppan and Ppan-
GFP, respectively) were constructed. U2OS cells were used for this approach, 
because they are very suitable for transient transfections. Ppan-GFP, as well as 
GFP-Ppan localized in transfected U2OS cells in nuclei and prominently nucleolar, 
indicating that the N- or C-terminal fusion of GFP to Ppan did not alter the localization 
behaviour of Ppan (Fig. 14).  
77% 
cells with predominant 
nucleolar staining: 
100% 
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Fig. 14. Localization of the Ppan protein fused to the green fluorescent protein (GFP). 
(a) Endogenous Ppan in HepG2 cells stained with monoclonal antibody 1C3. (b) Localization 
of Ppan-GFP and (c) GFP-Ppan fusion proteins in transiently transfected U2OS cells.  
 
 
In interphase cells Ppan localizes in the nucleus and nucleoli. To analyze the 
localization of Ppan during mitosis, HepG2 cells were examined in the metaphase. 
Ppan surrounded the condensed chromosomes in the metaphase plate, indicating 
that it is associated with the perichromosomal space during mitosis (Fig. 15).  
 
Fig. 15. Localization of Ppan during the metaphase of mitosis. Immunofluorescence 
microscopy of a single mitotic HepG2 cell, fixed with paraformaldehyde. Ppan was stained 
with 1C3 monoclonal antibody and DNA was counterstained with DAPI.  
 
 
3.3 The nucleolar localization of Ppan is dependent on RNA but not 
DNA 
 
Nuclear proteins can either be soluble or attached to nuclear structures. An example 
Results 
 
55 
is the tumor suppressor p53, which can be soluble in the nucleoplasm or be bound to 
nucleoplasmic complexes, like transcription complexes, or even be bound within the 
nucleolus (Rubbi and Milner, 2000; Klibanov et al., 2001). To study whether Ppan is 
soluble or attached to nuclear structures, HepG2 cells were either directly fixed or 
permeabilized prior to fixation to remove any soluble proteins. The fixed cells were 
then incubated with the Ppan specific antibody 1C3. Non-permeabilized and 
permeabilized cells stained nucleoplasmic and some nucleolar for Ppan (Fig. 16a 
and b).  
 
 
Fig. 16. Nucleolar localization of Ppan is dependent on RNA but not DNA. 
Immunofluorescence staining of Ppan. HepG2 cells were fixed with paraformaldehyde (a) or 
permeabilized (b,c,d) and treated with 15 µg/ml RNAseA (c) or 15 µg/ml DNAseI (d) for 30 
min prior to fixation. Ppan was immunostained with the 1C3 monoclonal antibody. DNA was 
counterstained with DAPI. 
 
 
The yeast homolog of Ppan, Ssf1, binds specifically to 27S pre-rRNA. To explore 
whether the localization of Ppan to the nucleolus involves binding to RNA, HepG2 
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cells were permeabilized and incubated with RNAseA for 30 min, followed by fixation 
and subsequent immunostaining with the specific Ppan antibody. Staining of Ppan 
was strongly diminished after treatment with RNAseA, suggesting that tethering of 
Ppan to the nucleoli is mediated by RNA-containing structures (Fig. 16c).  
To study if Ppan is associated to DNA in the nucleoli, permeabilized cells were 
incubated with DNAseI. Immunostaining showed that the nucleolar localization of 
Ppan was independent of DNA (Fig. 16d). 
 
In summary, the expression of Ppan is associated with cell proliferation, Ppan 
localizes nuclear and in 77 % of cells predominantly in nucleoli. Interestingly, the 
nucleolar localization of Ppan is dependent on RNA but not DNA. To shed light on 
the domain functions of Ppan and particularly on the domain(s) involved in nucleolar 
localization, several deletion mutants were generated. 
 
 
3.4 Generation of deletion mutants of Ppan 
 
The N-terminus, the left- and right-hand side of the Brix-domain, the coil-coil domain 
and the C-terminus with the two AT-hooks of Ppan were deleted (Fig. 17). Ppan 
wildtype and the mutants were cloned in the vector pRTS for conditional gene 
expression. 
 
 
3.5 Expression and localization of mutant Ppan proteins 
 
To verify that Ppan and the mutant Ppan proteins were correctly translated, human 
U2OS cells were stably transfected with pRTS coding for Ppan or the mutants.  Gene 
expression was induced for twenty-four hours with doxycycline (Fig. 18). Whole cell 
lysates were separated electrophoretically and blotted for detection with antibodies 
recognizing the HA-tag.  
PpanHA has an apparent molecular weight of 64 kDa, PpanΔBrixA of 48 kDa, 
PpanΔσ70 of 44 kDa, PpanΔcoc of 50 kDa, PpanΔN of 54 kDa, and PpanΔC of 36 
kDa. Ppan and all deletion mutants were expressed and appeared to be stable in 
U2OS cells, since no degradation was seen. Furthermore, the proteins migrated at 
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expected positions and were present in equal levels when compared to the loading 
control tubulin. 
 
 
Fig. 17. Human Ppan and the deletion mutants. PpanΔN lacks the first 30 amino acids, 
PpanΔBrixA the amino acids 31-171, PpanΔσ70 the amino acids 172-301, PpanΔcoc the 
amino acids 304-342 and PpanΔC the amino acids 343-473. Ppan and the Ppan mutants 
were constructed with a C-terminal HA-tag. 
 
 
 
 
  
Fig. 18. Western blot analysis of Ppan and the Ppan deletion mutants. U2OS cells were 
stably transfected with pRTS coding for Ppan and the deletion mutants. Twenty-four hours 
after induction of gene expression with doxycycline, cell lysates were electrophoresed and 
immunoblotted for detection with α-HA and α-tubulin antibodies. 
Results 
 
58 
Next the localization of Ppan and its deletion mutants was investigated in order to 
identify domains responsible for localization of the protein. Rat TGR-1 fibroblasts 
were used, because they can be transfected with high efficiency and are good 
selectable with antibiotics. TGR-1 cells were stably transfected with pRTS coding for 
Ppan and the deletion mutants and the expression of the genes was induced for 
twenty-four hours with doxycycline. The recombinant Ppan localized in the nucleus 
and predominately in nucleoli of the cells (Fig. 19). PpanΔBrixA showed the same 
staining pattern like the wildtype protein, indicating that the N-terminal part of the Brix 
domain is not essential for nucleolar localization. Interestingly, PpanΔσ70 stained the 
nucleoplasm in spot-like structures, excluding the nucleoli. The RNA binding σ70-like 
motif seems to be therefore important for nucleolar localization of Ppan. This 
phenotype will be discussed later on. The Ppan mutant lacking the coil-coil domain, 
PpanΔcoc, localized diffusely in the nucleoplasm, excluding some nuclear regions. 
The coil-coil domain is important for protein-protein interactions or dimerization of a 
protein. This suggests that Ppan requires a binding partner for nucleolar localization. 
The Ppan mutant lacking the N-terminal first 30 amino acids (PpanΔN), as well as the 
PpanΔC protein localized diffusely in the cytoplasm, the nucleoplasm and the 
nucleoli, showing that these domains regulate also the localization behaviour of the 
wildtype protein. 
 
 Fig. 19. Immunofluorescence studies for detection of localization of Ppan, and the 
deletion mutants. TGR-1 cells were stably transfected with pRTS coding for Ppan and the 
Ppan mutants. Twenty-four hours after induction of gene expression with doxycycline cells 
were fixed with methanol/aceton and stained with α-HA (3F10) antibody. Nuclear DNA was 
stained with DAPI.  
 
Deletion of the RNA-binding σ70-like motif in PpanΔσ70 delocalized the 
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overexpressed protein from nucleoli to discrete foci in the nucleoplasm of TGR-1 
cells (Fig. 19). The same delocalization was observed if PpanΔσ70 was expressed in 
HepG2 cells (Fig. 20) 
 
Fig. 20. The RNA binding σ70 like motif is crucial for nucleolar localization of Ppan. 
Ppan and PpanΔσ70 were expressed in HepG2 cells with doxycycline for 68h. After fixation 
with paraformaldehyde, cells were incubated with α-HA antibody (12CA5).  
 
In this work only wildtype Ppan and the mutants PpanΔσ70 and PpanΔN were further 
studied for reasons explained later on. 
 
 
3.6 PpanΔσ70 directs nucleophosmin, hRrp6 and Pes1, but not 
fibrillarin to discrete nuclear foci 
 
The nucleolar localization of Ppan appears to be dependent on its binding to 
nucleolar RNA structures (Fig. 16). The Ppan protein with a deletion in the RNA 
binding σ70 like motif, PpanΔσ70, delocalized from the nucleoli to discrete nuclear 
foci (Fig. 19 and 20). To analyze the nucleoplasmic structures formed by 
overexpression of PpanΔσ70, co-stainings of Ppan with different nuclear proteins 
were performed. Firstly two nucleoplasmic proteins, the PML protein, which locates in 
the PML bodies, and the sc-35 protein, a component of the nuclear splicing speckles, 
were examined.  U2OS cells were transiently transfected with PpanΔσ70-GFP 
expression vectors and cells were fixed 25 hours later (Fig. 21). The GFP-tagged 
PpanΔσ70 protein localized more prominently in nucleoli. Nevertheless, PpanΔσ70-
GFP displayed the characteristic nucleoplasmic spots, outside of nucleoli, as seen for 
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the HA-tagged form (Fig. 21). These spots did not co-stain with PML bodies (Fig. 
21a) or nuclear splicing speckles (Fig. 21b), suggesting that the spots formed by 
PpanΔσ70-GFP were not components of these nucleoplasmic structures. 
 
Fig. 21. PpanΔσ70-GFP does not co-localize with PML bodies or nuclear splicing 
speckles. Immunofluorescence analysis of single cells. PpanΔσ70-GFP was co-stained with 
PML and nuclear splicing speckles. PpanΔσ70-GFP was expressed in transiently transfected 
U2OS cells. Staining of paraformaldehyde fixed cells with (a) α-PML or (b) α-sc-35 (splicing 
speckle protein 35) specific antibodies. Right hand side: merge of the images. 
 
Do the newly formed nucleoplasmic structures represent disrupted nucleoli?  
To answer this question several nucleolar factors were co-stained with Ppan and 
PpanΔσ70 in stably transfected U2OS cells. Nucleophosmin is a highly abundant 
protein, which locates normally in the granular component of nucleoli. In U2OS cells 
expressing Ppan, nucleophosmin localizes nucleolar and diffusely in nucleoplasm. 
Interestingly after expression of PpanΔσ70, nucleophosmin was trapped in the newly 
formed nucleoplasmic spots and stained in addition in a ring pattern around the 
nucleoli (Fig. 22a). Another protein, the hRrp6 (human exosome component 10 or 
PM-Scl100) localizes diffusely in the nucleoplasm and predominately in nucleoli of 
cells (Schilders et al., 2007). The localization of hRrp6 could be confirmed (Fig. 22b).  
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Fig. 22. Ppan lacking the RNA-binding σ70-like motif directs nucleophosmin (a), 
hRrp6 (b), Pes1 (c), but not fibrillarin (d) in discrete nucleoplasmic foci. 
Immunofluorescence studies of single nuclei. Ppan or PpanΔσ70 were expressed in stably 
transfected U2OS cells for 40 hours. Cells were fixed with paraformaldehyde and stained 
with antibodies for HA, nucleophosmin, hRrp6, Pes1 or fibrillarin, respectively. DNA was 
counterstained with DAPI. Images were taken with a laser scanning confocal microscope. 
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Expression of PpanΔσ70 led to a partially redistribution of hRrp6 to nucleoplasmic 
foci, while the majority of hRrp6 remained in nucleoli (Fig. 22b). Pes1, component of 
the PeBoW complex, co-localized with Ppan in nucleoli. Like hRrp6, Pes1 was 
partially attracted to the PpanΔσ70 containing structures in the nucleoplasm, 
whereas the majority of the protein remained in nucleoli (Fig. 22c). Finally fibrillarin 
was analyzed as a component of the dense fibrillar component of nucleoli. Fibrillarin 
co-localized with Ppan in nucleoli of the cells and after expression of PpanΔσ70, 
fibrillarin did not leave its nucleolar localization to join PpanΔσ70 in nucleoplasmic 
structures (Fig. 22d) 
 
In summary, the mutation of distinct domains of the Ppan protein showed that the 
nucleolar localization of the protein requires the σ70 like motif and the coil-coil 
domain. Deletion of the RNA binding σ70 like motif delocalized the protein to discrete 
nucleoplasmic foci. PpanΔσ70 showed a dominant phenotype regarding the 
localization of nucleolar proteins nucleophosmin, hRrp6 and Pes1. These 
observations indicate a possible role of Ppan in maintaining the structural integrity of 
some nucleolar components and give hints for possible interactions of PpanΔσ70 
with nucleophosmin, hRrp6 and Pes1.  
 
Working with overexpressed Ppan and Ppan mutants causes artificial conditions in 
the cell. Since a monoclonal antibody against Ppan was available and tested for its 
specificity, the next goal was to study more explicit the endogenous protein, to 
approach more the physiological conditions in cultured cells.  
 
 
3.7 Endogenous Ppan is involved in ribosome biogenesis and cell  
  proliferation 
 
The yeast homolog of Ppan, Ssf1, is involved in ribosome biogenesis by controlling 
the correct order of rRNA processing. Furthermore, yeast cells with deletion of 
Ssf1/Ssf2 are not viable. To assess a role for human Ppan, small interfering RNA 
(siRNA) experiments were performed in human lung carcinoma cells H1299. These 
cells were chosen, because they can be easily transfected with siRNA and total 
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cellular RNA of these cells can be isolated in large amounts. H1299 cells were 
transfected on day 1 and 2 with either control- or ppan specific siRNA. The 
expression of Ppan was reduced, as monitored by Western blot analysis two days 
after the second siRNA transfection (Fig. 23a). To study a possible effect of ppan 
knock-down on the proliferation of the cells, H1299 cells were transfected with siRNA 
on days 1 and 2 and the total cell number was counted on days 5 and 8 (Fig. 23b). 
The proliferation of ppan knock-down cells was reduced compared to the control 
cells. 
In an attempt to study the possible involvement of Ppan in mammalian ribosome 
biogenesis, Northern blot analysis of H1299 cells transfected with siRNA was 
conducted. Cells were transfected on day 1 and 2 with control or ppan specific siRNA 
and total RNA was isolated 48 hours later. Northern blot analysis was performed with 
probes specific to the internal transcribed sequences 1 and 2 (ITS-1 and -2) of the 
rRNA precursors (Fig. 23d). Knock-down of ppan revealed a significant reduction of 
the mature 28S rRNA and more slightly of the 18S rRNA (Fig. 23d, lower pannel). 
Furthermore, analysis with a probe specific for the ITS-1 sequence showed a slight 
accumulation of the 47S, 45S and 41S rRNA precursors, compared to control siRNA 
transfected cells. When applying the probe for the ITS-2 sequence, the cells treated 
with ppan specific siRNA showed a slight increase in the 47S, 45S and 41S rRNA 
precursors and a decrease of the 12S rRNA precursor. More prominently a new 
rRNA form of about 25-26S was visible, which did not appear in the control cells.  
In conclusion, depletion of the endogenous Ppan protein leads to a reduced 
proliferation and to reduced levels of mature 18S and 28S rRNA. The processing of 
the rRNA is affected and an additional rRNA product appears. 
 
 
3.8 Interaction of Ppan with the PeBoW complex 
 
The yeast homologue of Ppan, Ssf1, interacts with many proteins among them Nop7, 
Erb1 and Ytm1, the homologues of Pes1, Bop1 and WDR12, components of the 
PeBoW complex in mammals (Hölzel et al., 2005; Rohrmoser et al., 2007). One 
interesting phenomenon described earlier in this work was that PpanΔσ70 protein 
was able to direct Pes1 to newly formed nuclear foci (Fig. 22). Therefore a possible 
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Fig. 23. siRNA knockdown of ppan leads to a reduced proliferation, reduction of 28S 
rRNA, and an additional rRNA product. (a) Immunodetection of Ppan and tubulin in 
Western blot analysis of cells transfected with control- and ppan specific siRNA. (b) 
Proliferation assay of cells treated with control or ppan-siRNA. (c) rRNA processing in 
mammalian cells with probes for ITS-1 (blue dot) and ITS-2 (red dot). (d) Northern blot 
analysis with probes ITS-1 and ITS-2 of H1299 cells transfected with control- or ppan-siRNA. 
Lower part: ethidium bromide (EtBr)-staining of the agarose gel.  
new processing 
intermediates 
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interaction of Ppan with Pes1 and the two other components of PeBoW, Bop1 and 
WDR12, was studied in co-immunoprecipitation experiments in U2OS cells. 
The antibody 1C3 precipitated only a very small amount of Ppan, approximately 1-2 
% of the cellular protein (Fig. 24, lane 2). The Ppan antibody precipitated about 10% 
of the cellular Pes1 and 1% of Bop1 (lane 2). The antibodies for Bop1, Pes1 and 
WDR12 precipitated Ppan (Fig. 24, lanes 4,5,6) approximately 1-5% of the cellular 
protein. Nevertheless, the results of the co-immunoprecipitation of Ppan with Pes1, 
Bop1 and WDR12 give a hint for a possible interaction. The quantity of the 
precipitated Ppan protein was very low and the quality of the experiment was not 
answering satisfactory the question of the interaction between Ppan and Pes1, Bop1 
or WDR12. Therefore, a second method was chosen to study the possible 
interactions, the so called Bimolecular Fluorescence Complementation assay (BiFC). 
 
 
 
 
 
Fig. 24. Ppan interacts with Pes1, Bop1 
and WDR12. Western blot analysis of co-
immunoprecipitation of endogenous Ppan 
with Pes1, Bop1 and WDR12 in U2OS 
cells. Cell lysates were immuno-
precipitated with α-Ppan, α-Bop1, α-Pes1 
and α-WDR12 antibodies followed by 
immunoblot detection using α-Ppan, α-
Pes1 or α-Bop1 antibodies. The co-
immunoprecipitation of Ppan with the 
PeBoW components is highlighted in the 
red box. An isotype specific mAb served 
as control. 
 
 
 
The BiFC-assay is very suitable for the visualization of interactions between proteins 
in living cells (Hu et al., 2002). Non-fluorescent fragments of yellow fluorescent 
protein (YFP) YN(1-154) and YC(155-238) reconstitute the fluorophore only when 
brought together by interactions between proteins covalently linked to each fragment 
of YFP. The complex allows the direct visualization of even a transient and weak 
interaction as the complex remains stable after formation. As a positive control for 
BiFC the interaction of Jun with Fos, two members of the basic-region/leucine-zipper 
(bZIP) family of transcription factors, was investigated (Hu et al., 2002). When 
plasmids carrying these two factors are co-expressed in cells, a strong BiFC signal is 
1 2 3 4 5 6 
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obtained in nuclei. A leucine zipper deletion in Fos (FosΔZip) that prevents Fos-Jun 
dimerization (Gentz et al., 1989) eliminates fluorescence complementation. The 
system was applied to study the interaction of Ppan with Pes1, Bop1 and WDR12. 
 
HepG2 cells were transfected with plasmids YN Ppan and YC Pes1, YC Bop1 or YC 
WDR12. Twenty-five hours post transfection cells were observed under a laser 
scanning confocal microscope using excitation at 488 nm and emission between 
529-560 nm wavelength to localize the YFP signal after potential interaction. BiFC 
signals through interaction of Fos and Jun served as a positive control (Fig. 25a). 
When cells were transfected with empty vectors (pBiFC-YN(1-154)* and pBiFC-
YC(155-238)*; simplified YN and YC respectively), no detectable BiFC signal was 
observed (Fig. 25b). No interaction was detectable in the negative control with Jun 
and FosΔZip (both gifts from Dr. Andreas Thomae, Helmholtz Centre Munich), from 
which the zipper domain, shown to be involved in the binding of Jun with Fos, is 
missing (Fig. 25c). Ppan and Pes1, as well as Ppan and WDR12 interacted in 
nucleoli of HepG2 cells after co-expression (Fig. 25d,f). The interactions were mainly 
restricted to the nucleoli. Although immunoprecipitation showed the interaction of 
Ppan with Bop1, there was no signal detectable in cells co-transfected with Ppan and 
Bop1 expression vectors (Fig. 25e). 
 
Ppan interacts with Pes1 and WDR12 in the nucleoli of HepG2 cells (Fig. 25). Pes1 
and WDR12 exist mainly incorporated in the PeBoW complex in the nucleolus 
(Rohrmoser et al., 2007). This suggests that Ppan interacts with the PeBoW complex 
in the nucleolus. The PeBoW complex is involved in the maturation of the 28S rRNA 
in mammalian cells (Hölzel et al., 2005, Grimm et al., 2006, Rohrmoser et al., 2007). 
By reducing the levels of the endogenous proteins by siRNA or expression of 
dominant negative forms of PeBoW components, the processing steps for the 28S 
rRNA are severely affected. Cells respond to this processing block with stabilization 
of p53. The exact mechanism how the stalled rRNA processing is signalled to 
activate p53 is still under investigation.  
 
Results 
 
67 
 
Fig. 25. BiFC analysis of Ppan and Pes1, Bop1 or WDR12. HepG2 cells were co-
transfected with plasmids (a) YN Jun with YC Fos (positive control), (b) YN and YC plasmids 
(negative control) and (c) YN Jun with YC Fos ΔZip (negative control) or YN Ppan with (d) 
YC Pes1, (e) YC Bop1 or (f) YC WDR12. Twenty-five hours post transfection living cells were 
analysed with a laser scanning confocal microscope. 
 
 
In yeast, Ssf1 is needed to prevent premature cleavage of rRNA and is therefore 
required to maintain the normal order of rRNA processing (Fatica et al., 2002). 
Preliminary data with siRNA knockdown of ppan showed that the mammalian protein 
shares functional similarities to the yeast homologue Ssf1. When Ppan interacts with 
the PeBoW complex in the nucleoli of HepG2 cells and controls rRNA processing, 
what happens to Ppan if rRNA processing is inhibited? To approach this question the 
cellular localization of Ppan was investigated after inhibition of rRNA processing. This 
was achieved by three different ways.   
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3.9 Prominent nucleolar localization of Ppan after inhibition of rRNA  
 processing  
 
Firstly, the processing of rRNA was disturbed by a dominant negative form of Pes1 
(dnPes1 M1), which inhibits the maturation of 28S rRNA and promotes the 
accumulation of the 36S rRNA. DnPes1 M1 is incorporated into the PeBoW complex 
and blocks its function (Grimm et al., 2006). Stably transfected U2OS cells were 
incubated with doxycycline to induce the bidirectional promoter for co-expression of 
dnPes1 M1 and eGFP (Fig. 26). DnPes1 expressing cells showed a prominent 
nucleolar staining of Ppan, recognized by the specific antibody 1C3. Cells negative 
for eGFP showed no prominent nucleolar staining for Ppan. It seems that Ppan’s 
localization is very abundant in nucleoli, if rRNA processing is inhibited by the 
overexpression of the dominant negative form of Pes1. 
 
 
     
 
Fig. 26. Inhibition of rRNA processing by a dominant negative form of Pes1 (dnPes1) 
leads to a prominent nucleolar staining of Ppan. (a) U2OS cells transiently transfected 
with pRTS-dnPes1 were treated with 1 µg/ml doxycycline to induce expression of dnPes1 M1 
and eGFP through the bidirectional promoter. Cells were fixed with paraformaldehyde and 
stained with the Ppan specific 1C3 antibody. DnPes1 expressing cells are eGFP positive, 
whereas non-expressing cells are negative for eGFP. (b) Principal function of pRTS-1. 
Doxycycline induces the bidirectional promoter (in red) for concomitant transcription of 
dnpes1 M1 and egfp.   
 
 
In a second approach the processing of rRNA was inhibited by 5-fluorouracil (5-FU) 
(Ghoshal and Jacob, 1994). 5-FU blocks rRNA processing at concentrations of 100 
µM entirely after six hours, while transcription of ribosomal genes remains unaffected 
(Mühl, 2007). 
HeLa, HepG2 and U2OS cells were treated with 5-FU for six hours and the 
localization of Ppan was examined (Fig. 27 and 28). One hundred cells were 
carefully examined for statistical evaluation of the localization of Ppan. About 63% of 
b a 
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untreated HeLa cells showed a predominant nucleolar staining of Ppan. After 
inhibition of rRNA processing by 5-FU, Ppan was detectable in 99 % of the cells (Fig. 
27a). Almost identical results were obtained, if U2OS cells were analyzed in similar 
experiments (Fig. 27b). 
 
 
Fig. 27. Nucleolar localization of Ppan after treatment of HeLa, HepG2 and U2OS cells 
with 5-FU. (a) HeLa, (b) HepG2, and (c) U2OS cells were treated with 100 µM 5-FU for six 
hours. After paraformadelhyde fixation cells were stained for Ppan with the 1C3 monoclonal 
antibody. Nuclei were counterstained with DAPI. Pictures were taken with a fluorescence 
microscope, by applying the same exposure time. 
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Fig. 28. Statistical analysis of 
nucleolar localization of Ppan in 
untreated and 5-FU treated cells. 
HeLa, HepG2 and U2OS cells 
were treated with 100 µM 5-FU for 
six hours.  One hundred cells of 
each cell type were examined for a 
predominan nucleolar localization 
of Ppan. 
 
Ppan was co-stained with fibrillarin in HepG2 cells to compare the localization of both 
proteins before and after 5-FU treatment. In figure 29 a representative cell was 
chosen for the analysis. Fibrillarin is a nucleolar protein, used widely as a marker for 
detecting nucleoli in immunofluorescence studies. Untreated cells showed a faint 
nucleolar staining of Ppan, whereas cells treated with 5-FU showed a strong 
nucleolar staining. After merging the two different profiles of Ppan and fibrillarin, a 
RGB profile of the two fluorescent pictures was made (ImageJ, plug in RGB profiler).  
 
 
 
 
Fig. 29. The signal 
intensity of Ppan 
increases in nucleoli of 
HepG2 cells after 
treatment with 5-FU. Cells 
were treated with 100 µM of 
5-FU for 6 hours, fixed with 
paraformaldehyde and 
stained for Ppan and 
fibrillarin. Images were 
captured with the laser 
scanning confocal micro-
scope. Pictures were 
merged and a RGB profile 
was drawn to study co-
localization. In the y-axis the 
RGB profiler shows the 
value of the fluorescence 
intensity in the logarithmic 
scale of 2. 
 
 
The fluorescence intensity of Ppan (red curves) in untreated HepG2 cells had a value 
- 5-FU + 5-FU 
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of about 4, whereas in 5-FU treated cells the intensity increased to a value of about 
32. The nucleolar fluorescence intensity of Ppan increased in this cell eight-fold after 
treatment with 5-FU. Fibrillarin (green curves) had a fluorescence intensity value of 
about 64 in untreated cells, whereas in 5-FU treated cells it had a value of about 128, 
which indicates a two-fold increase after treatment of cells with 5-FU. In summary the 
nucleolar staining of Ppan was strongly increased after treatment of the HepG2 cells 
with 5-FU. 
To investigate if the level of Ppan protein in HepG2 cells had changed upon 5-FU 
treatment, Western blot analysis was performed. Ppan protein levels remained stable 
after 5-FU treatment (Fig. 30). 
 
 
 
Fig. 30. Ppan protein level is not changed in 5-
FU treated cells. Western blot analysis of Ppan in 
total cell lysates of (a) untreated and (b) 5-FU 
treated HepG2 cells (100 µM, six hours). Equal cell 
mounts were lysed and immunoblotted for 
detection of Ppan and tubulin.   
 
In a third approach, the processing of rRNA was inhibited by the proteasome inhibitor 
MG-132. Stavrera and colleagues showed that many pre-rRNA processing factors 
were affected after proteasome inhibition. The proteasome was placed in the list of 
ribosome biogenesis regulators, because it caused additional ubiquitination of 
complexes associated with late processing factors, changes in nucleolar morphology 
and inhibition of pre-rRNA processing (Stavrera et al., 2006). Bastian Mühl in our 
laboratory confirmed that the proteasome inhibitor MG-132 inhibited processing of 
rRNA within 6 hours (Mühl, 2007).  
To study the localization of Ppan under proteasome inhibition, HepG2 cells were 
treated with MG-132 for six hours (Fig. 31). Over 140 cells were examined for the 
localization of Ppan (supplementary material). In untreated cells Ppan was nuclear 
and in about 77 % of the cells fixed with paraformaldehyde, Ppan localized nucleolar. 
In MG-132 treated cells only 11 % of cells showed a predominan nucleolar staining, if 
cells were fixed with paraformaldehyde. The immunofluorescence images indicated 
at a first glance a strong reduction of Ppan levels in the nucleus. To investigate if the 
level of Ppan protein in HepG2 cells had changed upon MG-132 treatment, western 
blot analysis was performed. Interestingly, Ppan protein levels remained stable after 
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MG-132 treatment (Fig. 32). 
 
 
 
Fig. 31. The N-terminal region of Ppan, recognized by monoclonal antibody 1C3, is 
masked after MG-132 treatment. HepG2 cells were treated with 10 µM MG-132 for six 
hours and fixed with paraformaldehyde for structure preservation or alternatively with 
methanol/aceton. Endogenous Ppan was visualized with the specific 1C3 monoclonal 
antibody. 
 
  
 
 
Fig. 32. Ppan protein level is not changed after 
MG-132 treatment. Western blot analysis of Ppan in 
total cell lysates of untreated and MG-132 treated 
HepG2 cells (10 µM, six hours). Equal cell amounts 
were lysed and immunoblotted for detection of Ppan 
and tubulin as a loading control. 
 
How can the discrepancy between the results of immunofluorescence and Western 
blot experiments be explained? Can treatment of cells with MG-132 lead to a 
masking of the 1C3 antibody epitope in Ppan? And is this mask fixed by 
paraformalehyde? In fact paraformaldehyde fixation of cells is structure preserving. In 
contrast, fixation with methanol/aceton destroys substructures and epitopes are 
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usually better presented than after paraformaldehyde fixation. 
When cells were fixed with methanol/aceton, Ppan localized in 88 % of the cells 
nucleolar (Fig. 31). Intriguingly, when cells were treated with MG-132, Ppan localized 
nucleolar in 96 % of 199 examined cells. This suggests that the N-terminal sequence 
of Ppan, which harbours the epitope of 1C3 antibody becomes masked and is no 
longer accessible for the antibody after MG-132 treatment. Thus, inhibition of rRNA 
processing probably does not affect the cellular localization of Ppan, but rather the 
interaction of its N-terminus with other cellular factors. 
 
Inhibition of the rRNA processing by expression of the dominant negative mutant of 
Pes1 or application of 5-FU, induced an increased signal intensity for Ppan in 
nucleoli. On the other hand, in the case of the proteasome inhibitor MG-132, the N-
terminal epitope of Ppan was not longer visible. However, the protein levels of Ppan 
did not change after perturbation of rRNA processing.  
In the next paragraph, I investigated if inhibition of rDNA gene transcription can 
induce a similar protection of the N-terminus of Ppan. 
 
 
3.10 Predominant nucleolar detection of Ppan after inhibition of 
rDNA transcription 
  
To answer the question of a stress-dependent detection behaviour of Ppan, the 
transcription of rDNA was disturbed by using the chemotherapeutic drug 
actinomycinD (ActD). Previous studies done in our laboratory (Mühl, 2007) confirmed 
that this substance had an effect on the transcription of the 47S precursor by the 
nucleolus specific RNA polymerase I. In this study ActD was applied at a 
concentration of 2.5 nM, which inhibits rDNA transcription entirely after 6 hours. 
The localization of Ppan was studied in HepG2 cells with the monoclonal antibody 
1C3 in untreated and ActD-treated cells (Fig. 33). Approximately one hundred 
untreated and ActD-treated cells were examined. Ppan localized in 77 % of the 
untreated cells nucleolar, whereas all ActD-treated cells showed a strong nucleolar 
staining of Ppan.  
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Fig. 33. Treatment of cells with ActD leads to predominant nucleolar detection of 
Ppan. HepG2 cells were treated with 2.5 nM ActD for 6 hours. After paraformaldehyde 
fixation cells were stained for Ppan with the 1C3 monoclonal antibody. Nuclear DNA was 
counterstained with DAPI. Pictures were taken with the same exposure time. 
 
To investigate the protein levels of Ppan, Western blot analysis of protein extracts of 
untreated and ActD-treated cells was performed (Fig. 34). The protein levels of Ppan 
were not changed in ActD treated cells. 
 
 
 
Fig. 34. Ppan protein levels are not changed in 
ActD treated cells. Western blot analysis of Ppan in 
total cell lysates of untreated and ActD treated HepG2 
cells. 2.5 nM ActD was diluted to the cell culture 
medium for 6 hours. Equal cell amounts were lysed 
and immunoblotted for detection of Ppan and tubulin.   
 
 
To study the nuclear distribution of the Ppan protein, nuclei and nucleoli of untreated 
and ActD treated HepG2 cells were prepared. Lysates of 1 % of isolated nuclei and 
10% of isolated nucleoli were separated in polyacrylamid gels, immunoblotted and 
analyzed with antibodies detecting RNA polymerase II (as a control for the purity of 
nucleolar preparations), Ppan, Hdm2 (for reasons explained below), nucleophosmin 
and fibrillarin (Fig. 35). The RNA polymerase II staining in nuclear preparations in 
lanes a and c and the lack of signals in isolated nucleoli in lanes b and d confirmed 
the proper isolation of nucleoli. Ppan was present in nucleoli of untreated and ActD 
treated cells (Fig. 35, lanes b and d). The levels of Ppan did not change in the 
nuclear fraction after ActD treatment, while a slight decrease was seen for the 
nucleolar fraction. Nucleophosmin could be detected in untreated and treated cells. 
Results 
 
75 
Fibrillarin was also detected in the nucleoli of untreated and ActD-treated cells (lanes 
b and d). The levels of nucleophosmin and fibrillarin decreased slightly in the 
nucleolar fraction of the ActD treated cells, as seen for Ppan (lane d). Treatment of 
cells with low concentration of ActD (5 nM) has previously been shown to stabilize 
p53 by disintegrating the p53/Hdm2 complex in the nucleoplasm and delocalizing 
Hdm2 to nucleoli (Ashcroft et al., 2000). In fact, the levels of Hdm2 were significantly 
increased in the nucleoli fraction of ActD-treated cells (Fig. 35d), whereas a small 
increase was seen only for the nuclei fraction (c).  
 
 
 
 
 
 
Fig. 35. Hdm2 localizes nucleolar after 
actinomycinD treatment. Western blot 
analysis of nuclear and nucleolar 
preparations from untreated and ActD-
treated HepG2 cells. 10 nM ActD was 
applied for 6 hours. 1% of nuclear (Nu) and 
10% of nucleolar (No) extracts were 
separated in SDS-PAGE followed by 
immunoblot using antibodies: α-Pol II 
(8WG16), α-Ppan (1C3), α-NPM (FC-6), α-
fibrillarin and α-Hdm2 (SMP-14).  
 
 
 
In summary, Ppan showed a predominant staining of nucleoli, although the entire 
protein levels did not change in the nuclei and nucleoli of ActD treated cells. 
 
 
3.11 ActinomycinD causes a structural rearrangement of Ppan and 
fibrillarin in the nucleoli 
  
Transcriptional arrest after ActD treatment induces the segregation of nucleolar 
components and the formation of unique structures termed nucleolar caps 
surrounding a central body (Shav-Tal et al., 2005). Nucleolar caps contain the pre-
rRNA and nucleolar proteins like fibrillarin. Other nucleolar factors, like 
a b c d 
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nucleophosmin, translocate in the nucleoplasm, when the rDNA transcription is 
inhibited. Until now only two components are known to localize to the central body of 
segregated nucleoli: p14Arf and the MRP RNA (Shav-Tal et al., 2005). To identify the 
region in which Ppan locates, double staining of Ppan and fibrillarin was performed in 
ActD treated HepG2 cells (Fig. 36).  
  
 
 
 
 
 
Fig. 36. Localization of Ppan in untreated and ActD treated HepG2 cells. (a) Ppan and 
fibrillarin localize in nucleoli of untreated cells. (b) Ppan co-localizes with fibrillarin in 
nucleoli of a single untreated cell. (c) Image of a single cell: Ppan localizes in the central 
body of segregated nucleoli after inhibition of rRNA transcription by ActD. HepG2 cells 
were treated with 10 nM ActD for six hours. Cells were fixed with paraformaldehyde and 
stained for Ppan (red) and fibrillarin (green). Nuclear DNA was counterstained with DAPI. 
Images were taken with a laser scanning confocal microscope and processed with ImageJ 
(plug-in VolumeJ). 1,2: magnified nucleoli of the merged image. 
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In untreated cells Ppan co-localizes with fibrillarin in the nucleoli (Fig. 36a and b). In 
nucleoli of ActD-treated HepG2 cells Ppan localizes in the nucleolar central body 
(Fig. 36c), whereas fibrillarin translocated to the nucleolar caps as described in the 
literature (Shav-Tal et al., 2005). 
 
Although Ppan showed an increased nucleolar detection in ActD treated cells, it 
differs from that of 5-FU treated cells. In the nucleoli of 5-FU treated cells fibrillarin 
co-stained with Ppan. Cells treated with ActD clearly showed segregated nucleoli 
with fibrillarin localizing to newly formed nucleolar caps surrounding the core domain. 
The core domain was negative for fibrillarin but positive for Ppan. Thus, inhibition of 
rRNA processing by 5-FU and rDNA transcription by ActD induced the reactivity of 
Ppan with the 1C3 antibody, albeit the different molecular action of both substances. 
 
 
3.12  Nucleolar localization of Ppan is independent of p53 
 
Treatment of cells with ActD activates p53 by disintegrating the inhibitory p53/Hdm2 
complex in the nucleoplasm (Ashcroft et al., 2000). Additionaly, overexpression of 
p53 was reported to repress rDNA transcription by RNA pol I by directly interfering 
with the interaction of the upstream binding factor (UBF) and selectivity factor (SL1) 
on the human rDNA promoter (Budde and Grummt, 1998; Zhai and Comai, 2000). 
Ppan localizes in the nucleoli of cells, when cells are treated with ActD. Is this 
increased nucleolar detection of Ppan a direct effect of transcription inhibition, 
probably due to recognition of nucleolar stress signals? Or does activated p53 
repress rDNA transcription and then as a second action promotes a nucleolar signal-
accumulation of Ppan? To answer these questions, two cell lines with and without 
endogenous p53 were used, namely HCT+/+p53 and HCT-/-p53 (B. Vogelstein, 
Johns Hopkins University, USA, provided by Dr. H. Gerhard, Helmholtz Centre 
Munich). Both cell types were treated with 2.5 nM actinomycinD for six hours and 
stained with Ppan for immunofluorescence studies. Untreated HCT cells showed only 
a faint nucleolar presence of Ppan (Fig. 37). Ppan localized strongly in the nucleoli of 
ActD treated cells, both in p53 positive and negative cells. It seems that the epitope 
was good accessible for the Ppan recognizing antibody after ActD treatment and this 
phenotype was not dependent on p53.  
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The reactivity of Ppan with the monoclonal antibody 1C3 increased strongly in 
nucleoli after inhibition of rDNA transcription by ActD in a stress sensitive behaviour. 
The increase in reactivity was independent of p53, indicating that p53 is not required 
for the stress-induced detection of Ppan in the nucleoli. On the other hand, it would 
be interesting to learn whether Ppan is involved in the activation of p53 after 
inhibition of rDNA transcription and processing of rRNA.  
A key factor in the control of p53 is Hdm2, which mediates the rapid degradation of 
p53. Hdm2 revealed nucleolar accumulation after treatment of cells with ActD (Fig. 
Fig. 37. Predominant nucleolar detection of Ppan ActD treated HCT cells is 
independent of p53. Immunofluorescence of endogenous Ppan in HCT -/- p53 and HCT +/+ 
p53 cells treated or not with 2.5 nM ActD for 6 hours. Ppan was stained with monoclonal 
antibody after fixation of cells. DNA was counterstained with DAPI.  
 
Results 
 
79 
35), and could potentially be involved in the unmasking of the 1C3 epitope. 
Therefore, the functional and physical interaction of Hdm2 and Ppan was studied. 
 
 
3.13 Stabilization of p53 by overexpression of Ppan 
 
To test whether Ppan is involved in the activation of p53 untransfected or stably 
transfected HepG2 cells (HepG2 Ppan, -PpanΔσ70 and -PpanΔN) were treated for 
72 hours with doxycycline to induce expression of respective proteins. Cellular 
lysates were separated in polyacrylamide gels and immunoblotted with antibodies to 
p53, Hdm2, tubulin, HA and Ppan (Fig. 38).  
  
 
 
 
 
Fig. 38. Ectopic production of Ppan, 
PpanΔσ70, and PpanΔN activates p53 
and Hdm2. Western blot analysis of cellular 
lysates of non- or stably transfected HepG2 
with pRTS-Ppan, -PpanΔσ70 and -PpanΔN. 
Cells were incubated in medium containing 1 
µg/ml doxycycline to allow expression of the 
genes. 72 hours later, cellular lysates were 
separated and immunoblotted for detection 
of p53 (DO-1), Hdm2 (SMP-14), α-tubulin, 
HA (3F10) and Ppan (1C3). The Ppan 
antibody recognizes endogenous and 
overproduced protein (in lanes b and c). 
 
Similar to p53, Hdm2 is an extremely unstable protein and only little amounts are 
detectable in cells (Fig. 38a). Recombinant Ppan was expressed at least 10-fold 
higher compared to endogenous Ppan (Fig. 38b). Expression of Ppan, PpanΔσ70 
and PpanΔN induced elevated levels of p53 and Hdm2.  
 
To investigate if the increase was due to stabilization of both proteins, the half-life of 
p53 and Hdm2 was investigated after treatment of cells with cycloheximide (CHX). 
Expression of Ppan was induced for 68 hours followed by addition of CHX for 
indicated times. Levels of p53 protein in control cells and cells expressing Ppan were 
a b c d 
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determined by Western blot analysis (Fig. 39). The half-life of the p53 protein was 
approximately 60 minutes in control cells, while p53 levels remained stable in Ppan 
overexpressing cells after addition of CHX. 
Overexpression of Ppan led to the stabilization of the p53 protein in U2OS cells. In 
contrast Hdm2 was destabilized and showed an increased turnover compared to 
control cells. The half-life of Hdm2 in control cells of about 90 minutes was reduced 
to about 30 minutes in Ppan overexpressing cells. In conclusion, overexpression of 
Ppan may stabilize p53 by the concomitant destabilization of the Hdm2 protein. Thus, 
stabilization of p53 could be a consequence of destabilization of Hdm2. 
 
 
Fig. 39. Overexpression of Ppan stabilizes p53 and destabilizes Hdm2. Expression of 
recombinant Ppan was induced in U2OS cells (U2OS Ppan) for 68 hours. Subsequently, 
cycloheximide (CHX, 50 µg/ml) was added for indicated times. Level of Ppan (HA), p53 (DO-
1), Hdm2 (SMP14) and tubulin were determined by immunoblot analysis.  
 
 
If overexpression of Ppan induces destabilization of Hdm2, what could be the 
mechanism? Does Ppan interact with Hdm2 upon nucleolar stress?   
 
 
3.14 Activation of p53 and Hdm2, but not Ppan, NPM or  
Pes1 by MG-132 
 
The study of the interaction of Ppan and Hdm2 is not trivial, since both proteins are 
not highly abundant in proliferating cells. Treatment of cells with the proteasome 
inhibitor MG-132 not only inhibits the degradation of proteins with high turnover rates, 
but also inhibits processing of ribosomal RNA. In fact, treatment of HepG2 cells with 
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MG-132 strongly increased the levels of Hdm2 and p53, but not Pes1, NPM and 
Ppan (Fig. 40). 
 
 
 
 
 
 
 
 
 
Fig. 40. MG-132 induces and increases 
the cellular levels of p53 and Hdm2, but 
not of Ppan, NPM and Pes1. HepG2 cells 
treated with 10 µM MG-132 were lysed at 
indicated time points after drug incubation. 
Western blot analysis of total cell lysates for 
Ppan (1C3), Hdm2 (SMP-14), NPM (FC-6), 
p53 (DO-1), Pes1 (8E9) and tubulin (DM1A). 
 
 
Similar to the nuclei/nucleoli separation experiment after ActD treatment described in 
Fig. 35, Hdm2 accumulated in the nucleoli of HepG2 cells upon MG-132 treatment, 
while Hdm2 in unstressed cells was detectable preferentially in the nuclear fraction 
(Fig. 41). 
 
 
 
 
 
Fig. 41. Stabilization and nucleolar 
localization of Ppan and Hdm2 after MG-
132 treatment. Western blot analysis of 
nuclear and nucleolar preparations form 
untreated and MG-132 treated HepG2 cells. 
10 µM MG-132 was applied for 6 hours. 1% 
of nuclear (Nu) and 10% of nucleolar (No) 
extracts were separated in SDS-PAGE 
followed by immunoblot analysis using 
antibodies: α-Pol II (8WG16), α-Ppan (1C3), 
α-Hdm2 (SMP-14), α-NPM (FC-6) and α-
fibrillarin.  
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3.15 Interaction of Ppan with Hdm2  
 
Since Hdm2 accumulates after MG-132 treatment of cells and co-localizes with Ppan 
in nucleoli, the possible interaction of both proteins was studied in co-
immunoprecipitation experiments. HepG2 cells were treated with MG-132 for six 
hours and prepared afterwards for immunoprecipitation with α-Ppan (1C3), α-Hdm2 
(SMP14 and D-12) and the isotype control for Ppan (α-Pol II). In extracts of untreated 
cells Ppan did not co-immunoprecipitate Hdm2 (Fig. 42, lane 2), whereas in extracts 
of MG-132 treated cells Ppan co-precipitated the stabilized Hdm2 (Fig. 42, lane 4).  
 
 
 
Fig. 42. Ppan interacts with Hdm2 after proteasome inhibition by MG-132. Western blot 
analysis of co-immunoprecipitations. HepG2 cells were left untreated or treated with 10 µM 
MG-132 for 6 hours. 10% of total lysate was loaded as input control. Ppan was precipitated 
by 1C3 monoclonal antibody, Hdm2 by a 1:1 mix of SMP-14 and D-12 antibodies. Control 
antibody (α-Pol II) with the same isotype to Ppan was used. Western blot was developed for 
Hdm2. 
  
 
Ppan thus interacts with Hdm2 after MG-132 treatment in HepG2 cells. Under these 
conditions, the N-terminal domain of Ppan, recognized by the antibody 1C3 is 
masked (Fig. 31). To investigate if this domain of Ppan was masked by the 
interaction with Hdm2, Ppan and the Ppan mutant PpanΔN lacking the N-terminal 
region were immunoprecipitated in HepG2 cells (Fig. 43). For this, HepG2 cells 
stably transfected with pRTS-Ppan and -PpanΔN were incubated in medium with 
doxycycline to express the proteins for 72 hours. Immunoprecipitation of Ppan with 
the HA antibody co-precipitated Hdm2 (Fig. 43a, lane 1) and vice versa precipitation 
of Hdm2 co-precipitated Ppan (same figure, lane 3). In cells producing PpanΔN, this 
truncated form was precipitated by HA and concomitantly co-precipitated Hdm2 (Fig. 
1 2 3 4 
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43b, lane1). When precipitating Hdm2 in the same cells the PpanΔN was also 
present in the precipitates (same figure, lane 3). The results suggest that this N-
terminal region is not essential for the precipitation of Hdm2 after MG-132 treatment. 
 
 
Fig. 43. Ppan and PpanΔN interact with Hdm2 after proteasome inhibition by MG-132. 
Western blot analysis of co-immunoprecipitations. HepG2 cells, stably transfected with 
pRTS-Ppan and -PpanΔN were incubated with 1 µg/ml doxycycline for expression of the 
proteins for 72 hours. Cells were treated with 10 µM MG-132 for 6 hours. 5% of the total 
lysate was loaded as the input control. Ppan and PpanΔN were precipitated by the HA 
antibody (12CA5), Hdm2 by 1:1 mix of SMP-14 and D-12 antibodies. As a control 
immunoprecipitations of the HA antibody (12CA5) in non-transfected HepG2 cells was 
performed. Antibodies HA (3F10) and Hdm2 (SMP-14) were used for Western blot analysis. 
 
To investigate the occurrence and subcellular localization of Ppan and Hdm2 
interaction in living HepG2 cells, the Bimolecular Fluorescence Complementation 
Assay (BiFC) was used. When cells were transfected with empty vectors (YN and 
YC), no detectable BiFC signal was observed (Fig. 25). In contrast, when Ppan and 
Hdm2 were expressed on co-transfected plasmids, BiFC signals mainly in the 
nucleoli and lower signals in nucleoplasm were noticed (Fig. 44a). Pes1 did not show 
any interaction with Hdm2 in BiFC analysis (Fig. 44b). Hdm2 interacted with p53 (Fig. 
44c) (pBiFC-YN(1-154)*-p53 or simplified YN p53 was a gift from Dr. Michaela 
Rohrmoser, Helmholtz Centre Munich) in nucleoplasm as expected, whereas Ppan 
showed with p53 a very weak BiFC signal in cytoplasm (Fig. 44d). 
In conclusion, Ppan interacts with Hdm2 and this interaction occurs preferentially in 
the nucleoli of HepG2 cells. A minor part of the proteins are interacting in the 
nucleoplasm. 
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Fig. 44. BiFC analysis of Ppan and Hdm2, p53 and Hdm2, Pes and Hdm2, Ppan and 
p53. HepG2 cells were co-transfected with plasmids coding for respective proteins. Living 
cells were examined for BiFC complex formation under a laser scanning confocal 
microscope twenty-five hours post transfection. Emission of YFP was measured between 
529-560 nm. 
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4. Discussion 
 
 
The key function of the nucleolus is the synthesis and processing of ribosomal RNAs 
(rRNAs) and their assembly into ribosomal subunits (r-subunits) (Busch and 
Smetana, 1970; Hadjiolov, 1985). Control of synthesis of new ribosomes is crucial for 
the regulation of growth and the process is tightly regulated in response to 
environmental conditions. One of the most intriguing novel roles of the nucleolus is 
the participation in sensing cellular stress signals and transmitting them to the p53 
stabilization system (Visintin and Amon, 2000; Rubbi and Milner, 2003; Olson, 2004; 
Mayer and Grummt, 2005). When ribosome biogenesis is blocked or disrupted, 
immediate signals activate the guardian of the genome p53. The signal transmission 
from nucleoli to p53 seems to be dependent on the type of stress and is discussed in 
many ways in the actual literature. In this study the protein Ppan was characterized 
and added to the list of nucleolar proteins involved in cellular stress response.  
 
4.1 What is the mechanism by which Ppan associates with nucleoli? 
 
The nucleolus is a nuclear compartment without being surrounded by a membrane. 
The residency of proteins and RNAs in the nucleolus is coordinated through an 
interaction network. For instance, the nucleolar localization of aprataxin is dependent 
on its interaction with the nucleolar protein nucleolin and on active rDNA transcription 
(Becherel et al., 2006). By depleting nucleolin with a specific siRNA, aprataxin 
delocalizes from the nucleoli. Similarly, the protein Bop1 requires its binding partner 
Pes1 for stable association with the nucleolus (Rohrmoser et al., 2007). 
To answer the question of promoting Ppan’s localization in the nucleolus, I firstly 
performed RNAseA and DNAseI digestion experiments. The nucleolar residency of 
Ppan was clearly independent of DNA but probably dependent on its binding to RNA. 
Of course it cannot be excluded under these experimental conditions that Ppan is 
interacting with another protein, which confers the nucleolar localization. A 
hypothetical interactor of Ppan could be bound to RNA and translocate highly 
sensitive after RNAseA treatment out of the nucleolus. To find out if Ppan itself is 
translocating after loss of RNA binding, I generated a mutant form of Ppan, missing 
the RNA binding σ70 like motif. Immunofluorescence analysis of PpanΔσ70 
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supported the observation that its RNA interaction domain is important to anchor the 
protein into the nucleolus. More importantly this experiment showed that Ppan itself 
is bound to RNA and the translocation after RNAseA treatment is probably not a 
secondary effect promoted by another protein. RNAseA treatment impacts at least 
two types of RNAs in the nucleolus: small nucleolar RNAs (snoRNAs) and pre-
rRNAs. Which type of the RNA is bound to Ppan is still unknown. Studies on the 
yeast homologue of Ppan, Ssf1, revealed an interaction with the yeast 27S rRNA, the 
precursor of 5.8S and 25S rRNA (Fatica et al., 2002). The 27S rRNA in yeast 
corresponds to the 32S rRNA in mammalian cells. This could be a candidate RNA for 
human Ppan, assuming that it would posses the same role in human cells. This 
speculation has to be verified by further studies.  
The mutant of Ppan lacking the coil-coil domain was excluded from the nucleoli and 
dispersed throughout the nucleoplasm. The coil-coil domain is a protein-protein 
interaction domain, which indicates that Ppan needs probably to be bound to another 
nucleolar protein, additionally to RNA, for residing in the nucleolus. The regulation of 
nucleolar localization of Ppan seems to be more complex. 
The nucleoli are disassembled during mitosis. The localization of nucleolar factors 
during mitosis can vary. For example, some factors, including several snoRNAs, 
move toward the nuclear envelope and associate either with the condensing 
chromosomes forming a layer surrounding the chromosomes called the 
perichromosomal region (Gautier et al., 1992, van Hooser et al., 2005) or are found 
in the cytoplasm and appear to become associated with the spindle apparatus in the 
cytoplasm (Gassmann et al., 2005; Hernandez-Verdun and Gautier, 1994). During 
mitosis Ppan was found associated with the perichromosomal region. The 
localization of proteins in the perichromosomal region has been observed in a variety 
of plant and animal cells and is suggested to have a role in the equal distribution of 
proteins to daughter cells required for early nuclear and nucleolar assembly following 
mitosis (van Hooser et al., 2005). This would imply that Ppan might play a role in the 
early assembly of nuclear and nucleolar structures. 
 
4.2  Binding partners of Ppan 
 
For identification of interaction partners of Ppan, I decided to study its molecular 
associations with the components of the PeBoW complex, Pes1, Bop1 and WDR12. 
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The homologues of these three proteins in yeast are interactants of Ssf1. Indeed 
Ppan interacted with Pes1, Bop1 and WDR12, as did Ssf1 with Nop7, Erb1 and Ytm1 
(Fatica et al., 2002).  
Two interactions of Ppan in human cells have been described in the past, both are 
involved in ribosome biogenesis. Nop56p is associated with pre-ribosomal 
ribonucleoprotein complexes (Hayano et al., 2003) and is a component of the box 
C/D small nucleolar ribonucleoprotein complexes that direct 2’O-methylation of pre-
rRNA during its maturation (Gautier et al., 1997). The second protein is the DEAD-
box RNA helicase DDX47 (Sekiguchi et al., 2006). RNA helicases from the DEAD-
box family are present in almost all organisms and have important roles in RNA 
metabolism (de la Cruz et al., 1999). DDX47 localizes nucleolar and is probably 
involved in the processing of the primary rRNA transcript and mRNA splicing 
(Sekiguchi et al., 2006). The main role of DDX47 is likely to be in 60S ribosome 
subunit assembly. 
Ppan interacts with Pes1, Bop1, WDR12, Nop56 and DDX47, proteins involved in the 
processing and maturation of the large subunit 28S rRNA. Ribosome biogenesis in 
eukaryotes involves a coordinated and sequential assembly of a large number of 
protein factors in ribonucleoprotein complexes that contain precursors of the rRNAs 
(Saveanu et al., 2003).  
The role of Ppan in the regulation of rRNA processing is not clear. In yeast, deletion 
of Ssf1 leads to a delay in cleavage at sites A0, A1 and A2 of the pre-rRNA precursor 
(Fatica et al., 2002). By interacting with rRNA processing factors, Ppan could control 
the right order of rRNA processing and prevent premature processing, as does Ssf1 
in yeast. The siRNA knock-down of ppan in this work gave first hints for a similar role 
in mammalian cells. In the case of stalled ribosome biogenesis, Ppan might form new 
complexes which are involved in signalling to cell cycle checkpoints. 
An intriguing and novel result of this work is the interaction of Ppan with Hdm2. The 
interaction has been shown for endogenous and overexpressed Ppan under 
conditions where Hdm2 is stabilized through inhibition of the proteasome. The 
interaction could be confirmed by BiFC analysis in living cells, and occurred 
predominantly in the nucleolus. The isolation of nucleoli of HepG2 cells confirmed 
that Ppan and Hdm2 were present in this nuclear compartment during proteasome 
inhibition by MG-132. This opens new insights in the function of Ppan in mammalian 
cells, placing Ppan into the group of nucleolar proteins involved in recognition and 
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transmission of nucleolar perturbation to the cellular stress response machinery. The 
implications of this interaction are discussed later in this chapter. 
 
4.3  Nucleolar detection of Ppan changes after nucleolar stress 
 
The N-terminus of Ppan is masked in nucleoli of about 20 % of proliferating cells. 
Nucleolar stress, like 5-FU or ActD leads to an unmasking of the N-terminus of Ppan, 
which is then accessible for the 1C3 antibody in all nucleoli of treated cells. In 
contrast, the N-terminus of Ppan in nucleoli of cells treated with MG-132 was nearly 
completely inaccessible to the 1C3 antibody in immunofluorescence analysis. 
However, the 1C3 antibody efficiently binds to denatured Ppan protein from MG-132 
treated cells, as evidenced by Western blotting of cellular proteins. Thus, Ppan 
seems to undergo a conformational change or a protection of the epitope by other 
factors upon nucleolar stress. 
Could the masking of the N-terminus be dependent on the cell cycle phase of the 
individual cell? For example, the proteasome inhibitor MG-132 leads to a cell cycle 
arrest in the G2/M phase (Kim et al., 2004) and the N-terminus of Ppan could be 
masked in a G2/M specific manner, whereas 5-FU synchronizes the cells in the G1 
phase (Yoshikawa et al., 2001), where no masking was observed. However 
doxorubicin (O’ Loughlin et al., 2000) and oxaliplatin (William-Faltaos et al., 2006) 
also lead to a G2/M phase arrest but did not induce a masking of the N-terminus of 
Ppan. Instead all treated cells showed a clear nucleolar staining of Ppan (data not 
shown). The observations with MG-132, 5-FU, doxorubicin and oxaliplatin support 
the notion that the epitope masking of Ppan is probably not dependent on the cell 
cycle phase, but rather a consequence of the individual stress situation. 
 
4.4 Potential role of Ppan during inhibition of the rRNA processing  
 
A speculated mechanism of 5-FU cytotoxicity features the incorporation of 5-FU into 
RNA. Evidence comes from experiments showing that co-treatment of cells with 
uridine, but not thymidine, can relieve the cytotoxic effects of 5-FU (Engelbrecht et 
al., 1984). 5-FU is rapidly incorporated into pre-rRNA in treated cells, since rRNA is 
the most abundant class of RNA produced in proliferating cells. Experiments suggest 
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that 5-FU may cause inhibition of processing at early steps, probably at the primary 
processing site without affecting ribosomal gene transcription (Cory et al., 1979; 
Greenhalgh and Parish 1989 and 1990; Ghoshal and Jacob, 1994). Goshal and 
Jacob (1994) proposed, that the drug-induced inhibition of pre-rRNA processing was 
due to alteration in the activity and/or synthesis of a trans-acting factor rather than 
inefficient utilization of 5-FU-containing RNA. More recent evidence has refocused 
attention on rRNA processing being a target for 5-FU, since genome-wide screens in 
Saccharomyces cerevisiae for gene products sensitive to the drug identified 
components of the rRNA processing pathway (Lum et al., 2004). Treatment of a 
yeast heterozygous deletion pool with 5-FU revealed a drug-induced 
haploinsufficiency for eight genes, four of them being components of the exosome. 
Interestingly ssf1, the homologue of human ppan, was one of these eight target 
genes, as well as nop4, mak21 and rrp15. Ssf1 has been found in a complex with 
Nop4, Mak21 and Rrp15 (Gavin et al., 2002; Fatica et al., 2002, Krogan et al., 2006), 
which are required in yeast for processing and maturation of the large ribosomal 
subunit. Ssf1 seems to be important for the survival of the yeast cells after 5-FU 
induced ribosomal stress. 
Using DNA microarrays to analyze the effect of 5-FU to the yeast transcriptome, it 
was found that the drug causes firstly the accumulation of polyadenylated fragments 
of the 27S rRNA precursor and second, that 5-FU antagonized the ability of the 
exosome to degrade the accumulated polyadenylated rRNAs (Fang et al., 2004). In 
the same study it was shown that production of poly(A)+ 27S rRNA may be a general 
result of inhibition of rRNA processing. The existence of polyadenylated rRNA was 
confirmed for human cells (Slomovic et al., 2006).  
Ppan may be part of a similar surveillance pathway in mammalian cells. Evidence for 
this assumption comes from the observation that the PpanΔσ70 mutant can bind and 
direct the exosome subunit hRrp6 to nuclear spots. This redistribution was observed 
also for other nucleolar factors. Since the RNA binding motif of the σ70 domain 
usually retains Ppan in the nucleolus, Ppan (with other factors) might recruit the 
exosome to polyadenylated rRNA. 
Proteasomal regulation has been implicated in many processes, including cell cycle 
progression, transcription and antigen processing (Hershko and Ciechanover, 1998; 
Goldberg, 2003; Muratani and Tansey, 2003; Wojcik and DeMartino, 2003). Indirect 
evidence was given for the participation of the ubiquitin-proteasome system in 
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ribosome biogenesis. In mammalian cells complexes associated with early and late 
pre-rRNA processing factors contain ubiquitinated components. Inhibition of the 
proteasome induces additional ubiquitination of complexes associated with late 
processing factors, changes in nucleolar morphology and inhibition of pre-rRNA 
processing (Stavrera et al., 2006). MG-132 is a potent inhibitor of the proteasome. In 
my work, MG-132 treatment led to a stabilization and interaction of Hdm2 with Ppan. 
Primarily the proteasome inhibitor was used to stabilize Hdm2, in order to detect it 
and have it in good quantities for the studies. However, MG-132 does not only 
stabilize proteins, but also inhibits ribosome biogenesis. The mechanims of this 
inhibition is not yet clear. However, a consequence could be the interaction of Ppan 
with Hdm2 and the sequestration of Hdm2 in the nucleolus. The nucleolar interaction 
of Ppan and Hdm2 could be demonstrated in this work by BiFC experiments. Thus, 
Ppan could be a possible link between inhibition of ribosome biogenesis and p53 
stabilization. 
Sun et al. (2007) showed that the activation of p53 after 5-FU treatment involves the 
interactions of Hdm2 with the ribosomal proteins L5, L11 and L23. The stabilization of 
p53 after inhibition of rRNA processing seems to be more complex regulated, 
possibly by several nucleolar factors. 
Nucleophosmin (NPM) is a multifunctional nucleolar phosphoprotein, which is 
constantly shuttling between the nucleolus and cytoplasm (Borer et al., 1989). NPM 
functions as a ribosome assembly and transport protein, binds to proteins containing 
nuclear localization sequences for their import, acts as a molecular chaperon and is 
essential in centrosome duplication (Kurki et al., 2004). NPM is redistributed from the 
nucleolus to the nucleoplasm in response to cytotoxic and genotoxic stress (Wu and 
Yung, 2002; Wu et al., 2002; Yang et al., 2002; Rubbi and Milner, 2003). The 
interaction of NPM with Hdm2 in the nucleolus after inhibition of the proteasome by 
MG-132 (Kurki et al., 2004) was extended in this work to Ppan. Since the Ppan Δσ70 
mutant attracts NPM to the newly formed nuclear foci, a multiple complex of NPM, 
Hdm2 and Ppan could be envisaged. Importantly, the N-terminus of Ppan becomes 
masked after MG-132 treatment, which implicates a new interaction of Ppan with 
another protein under these conditions. Whether NPM or Hdm2 could be the masking 
interaction partner has to be studied in future experiments. 
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4.5 Ppan localizes in the core body of segregated nucleoli 
 
Nucleoli of cells show great variability at different stages of cellular metabolic activity. 
A special phenotype is the nucleolar segregation, which occurs under physiological 
circumstances, when transcription is shut down during differentiation and 
development and can be mimicked by drug-induced transcriptional arrest (Dousset et 
al., 2000; Shav-Tal et al., 2005). Additionally, nucleolar segregation is observed in 
quiescent cells (Malatesta et al., 2000) and can be followed by nucleolar reassembly. 
This mechanism provides flexibility to the cell to maintain a certain degree of 
nucleolar structure after shut off of rRNA transcription. In segregated nucleoli the 
fibrillar and granular zones disengage and form separate but juxtaposed structures. 
These structures show cap-like formations around the core body of the segregated 
nucleolus. The most nucleolar factors delocalize after transcriptional arrest to newly-
formed cap-structures, like fibrillarin (Shav-Tal et al., 2005) or translocate to the 
nucleoplasm, like nucleophosmin (Shav-Tal et al., 2005) and hRrp6 (Brouwer et al., 
2001). The presence of Ppan in the core body of the segregated nucleoli is a striking 
observation. Until now only two components have been reported to reside to this site: 
the tumor suppressor p14Arf and the MRP RNA. p14Arf activates p53, by 
sequestration of Hdm2 into the nucleoli after oncogenic stress induced by 
overexpressed or mutated oncogenes, such as Myc (Weber et al., 1999) or Ras 
(Palmero et al., 1998). The MRP RNA is involved in the cleavage and maturation of 
precursor rRNA (van Eenennaam et al., 2000). The residence of Ppan in the core 
body of stressed nucleoli might indicate that it has a function in retaining the 
structural integrity of the nucleolus. When the inhibition is abolished, the segregated 
nucleoli can reshape and Ppan could be involved in this re-establishment, for 
example by recruitment of other nucleolar factors. 
 
4.6 Ppan co-localizes with Hdm2 in nucleoli when the rDNA 
transcription is inhibited 
 
The RNA polymerase I activity is responsible for rRNA synthesis and the integrity of 
the nucleolus. Nucleolar proteins, like nucleophosmin, nucleolin, and many other 
rRNA binding factors translocate from the nucleolus to the nucleoplasm when the 
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transciption by the RNA polymerase I is inhibited (Chan, 1992; Kalousek et al., 2005; 
Shav-Tal et al., 2005). Actinomycin D (ActD) is a chemotherapy drug, which has 
been used in the treatment of a variety of human cancers for many years. At high 
concentrations (e.g. >30 nM) ActD causes DNA damage and inhibits transcription of 
all three classes of RNA polymerases, whereas at low concentrations (e.g. <10 nM) 
ActD selectively inhibits the RNA polymerase I-dependent transcription and thus 
ribosomal biogenesis (Perry and Kelley, 1970; Iapalucci-Espinoza and Franze-
Fernandez, 1979). Treatment with low levels ActD (5 nM) has previously been shown 
to stabilize p53 by disintegrating the p53/Hdm2 complex through localization of Hdm2 
to nucleoli of treated cells (Ashcroft et al., 2000). In this work I could show the co-
localization and interaction of Ppan with Hdm2 after treatment with low doses of ActD 
in nucleoli of HepG2 cells. Recent studies have shown the interaction of Hdm2 and 
L11 in nucleoli of ActD treated cells (Lohrum et al., 2003). Taken together a stress-
signalling complex containing L11 and Ppan can be proposed that sequesters Hdm2 
in the nucleolus upon stress. This has to be verified in future studies. 
In the studies of Andersen et al. (2003) the translocation of Ppan from the nucleolus 
to the nucleoplasm has been described after transcription inhibition by ActD. This is 
not consistent with results in my work. However, Andersen and his colleagues used 
for their study 5 µg/ml (4 µM) ActD, thus about 1000 fold higher concentrations where 
nucleoli are almost entirely disrupted and may explain why Ppan was found to 
translocate to the nucleoplasm in the work of Andersen et al. (2003). 
 
4.7  Why is Ppan a tumor suppressor? 
 
Ppan has been discussed to be a tumor suppressor in human HF cells (Welch et al., 
2000). The HF cells originate from the HeLa cervical cancer cell line, which is 
infected by the human papillomavirus (HPV). The HPV E6 oncogene targets the p53 
protein for ubiquitination and rapid degradation (Huibregtse and Beaudenon, 1996). 
Interestingly, the HF cells show a stabilization and reactivation of the p53 protein 
through a reduced binding of the E6 protein to p53 (Athanassiou et al., 1999). Thus, 
Ppan can act as a tumor suppressor in a p53 positive backround. The mechanism 
how Ppan functions as a tumor suppressor is unknown.  
Tumor suppressors function either by controlling the cell cycle or apoptosis or are 
involved in DNA damage repair. The major representative is the tumor suppressor 
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p53. Elevated levels of p53 can inhibit cell growth or induce apoptotic cell death. p53 
functions as a sequence-specific transcription factor and regulates the expression of 
target genes involved in growth arrest, apoptosis, DNA repair, senescence or 
differentiation (Vogelstein et al., 2000; Smeenk et al., 2008). The p53 protein levels 
and activity are under tight control.  
Proteins, which can govern the activity of p53 can also act as tumor suppressors, like 
p14Arf. p14Arf activates p53 directly by interaction with the negative regulator of p53, 
Hdm2. Hdm2 plays a pivotal role in regulating p53 protein levels and is involved in its 
degradation (Haupt et al., 1997; Kubbutat et al., 1997). Hdm2 binds to the N-terminus 
of p53 and thereby facilitates the ubiquitination and subsequent proteasome-
mediated degradation of the p53 protein. Several mechanisms were discussed by 
which p53 is stabilized. These mechanisms target either p53 or Hdm2 (Ashcroft et 
al., 2000). In the case of Hdm2, Hdm2 can interact with ribosomal proteins S7 (Chen 
et al., 2007), L5 (Marechal et al., 1994), L11 (Lohrum et al., 2003, Zhang et al., 2003) 
and L23 (Jin et al., 2004), if these proteins are supplied in excess if ribosome 
biogenesis is blocked. The fact that Hdm2 interacts with ribosomal proteins suggests 
a link by which cells can coordinate cell growth with proliferation. The multiple Hdm2-
interacting ribosomal proteins may have a synergistic effect to bring about a quick 
and strong inhibition of Hdm2 when ribosomal damage occurs (Jin et al., 2004). 
Sequestration of Hdm2 to the nucleolus has also been observed by the tumor 
suppressor p14Arf (Tao and Levine, 1999).  
The above information was integrated to understand a possible role of Ppan in 
human cells. Ppan interacts with Hdm2 and thereby stabilizes p53. How could this 
stabilization of p53 be managed? Two possibilities can be considered: the disruption 
of the nucleoplasmic Hdm2-p53 complex by, for example, sequestration of Hdm2 to 
the nucleolus or the influence of Ppan on the stability of Hdm2. 
Indeed, the Ppan-Hdm2 interaction was mainly nucleolar, as seen by the BiFC 
analysis. This could indicate a sequestration of Hdm2 into the nucleoli, preventing the 
nucleoplasmic Hdm2-p53 complex. As a consequence p53 is no longer bound by 
Hdm2 and therefore not subjected to Hdm2-mediated proteasomal degradation.  
Recent studies showed that regulated Mdm2 auto-degradation is an important 
mechanism by which p53 is activated in cells treated with DNA damaging agents 
(Stommel and Wahl, 2004). This led to a second proposal for Ppan as a possible 
activator of p53, by destabilizing Hdm2. Overexpressed Ppan and the truncated 
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Ppan form PpanΔσ70 showed a clear induction of p53 and also of Hdm2. PpanΔN 
activated p53 but failed to induce strongly Hdm2. When studying the localization of 
the PpanΔN, a large part of this protein mislocalized to the cytoplasm, whereas a 
small part localized nucleolar and slightly nucleoplasmic. This could speculate that 
the activation of Hdm2 is performed only when Ppan localizes nuclear 
(nucleoplasmic and nucleolar), thus under normal conditions. Overproduced Ppan 
could clearly destabilize the activated Hdm2 by reducing the half-life of the protein. 
The mechanism how it is established is completely unknown. Phosphorylation of 
Hdm2 is likely to play a role in degradation (Stommel and Wahl, 2004). The 
phosphorylation is thought to be at multiple sites and by multiple DNA damage-
activated kinases of the PI 3-kinase family, such as ATM of ATR (Stommel and Wahl, 
2005). In addition to phosphorylation, it was shown that the intrinsic ubiquitin ligase 
activity is required for Hdm2 destabilization. A specific domain of Hdm2, the RING 
domain, is involved in this activity. The RING domain binds also accessory proteins 
that might contribute to the regulation of ubiquitination. MdmX might be the most 
interesting candidate for this role. MdmX interacts and stabilizes Hdm2 through its 
ring domains (Tanimura et al., 1999; Sharp et al., 1999). MdmX was found to be an 
important regulator of p53 activation after ribosomal stress (Gilkes et al., 2006). It 
sequesters p53 to inactive Mdmx-p53 complexes, preventing the p53 activation 
through inhibiting of its DNA binding activity. Taken the data together, Ppan could 
lead to a destabilization of Hdm2, possibly by recruiting kinases to phosphorylate 
Hdm2. Furthermore an interaction with Hdm4 (human homologue of MdmX) could 
lead to the destabilization of Hdm2. These speculations are open to be investigated 
in future studies. 
It would be also possible that Ppan can stabilize p53 in conditions other than 
nucleolar stress. c-Myc can elevate the expression of Ppan and other nucleolar 
proteins, such as Pes1, Bop1 and WDR12, suggesting that Ppan could also play a 
role in mediating induction of p53 in response to Myc. The preliminary results 
showing that Ppan is able to stabilize p53 could explain the role as a postulated 
tumor suppressor. 
Hdm2 has been extensively studied as a regulator of p53. Nevertheless, there is 
considerable evidence that Hdm2 has p53-independent functions (Ganguli and 
Wasylyk, 2003). Hdm2 has been shown to interact with a large number of proteins 
besides p53. The retinoblastoma protein (pRB) is a tumor suppressor that functions 
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similar to p53 in cell cycle inhibition and apoptosis. Hdm2 interacts with pRB and 
modulates its activity, the pRB mediated G1 arrest (Xiao et al., 1995). The Mdm2 
binding protein (MTBP) induces a G1 arrest in a p53-independent manner and this 
arrest can be inhibited by interaction of MTBP with Hdm2 (Boyd et al., 2000). Hdm2 
binds and promotes the degradation of Numb, a protein involved in differentiation 
(Juven-Gershon et al., 1998). The DNA polymerase ε is involved in DNA repair, 
recombination, replication, damage sensing and chromatin remodelling and interacts 
with Hdm2 (Vlatkovic et al., 2000).  
The p53-independent functions of Hdm2 could have implications on the Ppan-Hdm2 
interaction. Ppan could act as a tumor suppressor independently on p53. The 
unmasking of the N-terminus of Ppan after ActD treatment was independent of p53 in 
HCT cells. This implicates that the unmasking of Ppan is an action before, and 
possibly needed for the activation and stabilization of p53 or the function of Ppan is 
independent on p53 in these cells. The observation that overexpression of Ppan is 
followed by activation and stabilization of p53 suggests, that Ppan may regulate the 
p53 pathway. Nevertheless other mechanisms have to be considered in future 
studies. 
  
4.8 Model for action of Ppan in human cells 
 
The results obtained during this thesis led me propose the following models (Fig. 
45a-c): 
Ppan localizes in the nucleolus in an RNA- and protein-interaction dependent manner 
(Fig. 45a). It interacts with factors involved in the processing of rRNA. After nucleolar 
perturbation most nucleolar factors delocalize from the nucleolus to the nucleoplasm. 
Ppan remains in nucleoli of cells with defects in rRNA processing or rDNA 
transcription and this implicates that it has probably a function in retaining the 
structural integrity of the nucleolus. 
The inhibition of rDNA transcription causes the segregation of nucleoli, which form a 
core component (or central body) surrounded by nucleolar caps (Fig. 45b). The 
majority of the nucleolar factors translocate to the nucleoplasm (like nucleophosmin 
(NPM) or hRrp6) or to the nucleolar caps (like fibrillarin). Ppan localizes intriguingly in 
the core component. Since Ppan interacts with Hdm2 in the nucleoli and L11 
interacts with Hdm2 after ActD treatment, a multimeric complex of L11-Hdm2-Ppan 
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could be discussed. 
The inhibition of rRNA processing leads to polyadenylated rRNAs, which are 
degraded by the exosome (Fig. 45c). Since Ppan interacts with nucleolar RNA and 
binds to the exosome component hRrp6, it could sequester the latter to 
polyadenylated rRNA. The N-terminus of nucleolar Ppan is masked after treatment of 
cells with the proteasome inhibitor MG-132 implicating changes in interactions. Ppan 
interacts under rRNA processing inhibition with Hdm2 in nucleoli, liberating p53 from 
nucleoplasmic p53-Hdm2 complexes, which leads to activation of p53. Ppan attracts 
probably NPM in a multimeric complex for the coordination of nucleolar malfunction 
and cellular response.  
 
4.9 Outlook 
 
The studies of this thesis reveal a mechanism for the inhibition of Hdm2 and 
activation of p53 through an interaction of Hdm2 with Ppan. Many questions are still 
open to investigate. Ppan has two nucleic acid binding domains. Firstly, the σ70 
domain is important for binding to nucleolar RNA and the nucleolar localization of 
Ppan. Secondly, Ppan possesses two AT-hook domains, which bind probably to AT-
rich sequences in DNA. The nature of bound nucleic acid would give more 
information for the stress regulated function of Ppan. 
The interaction of Ppan and Hdm2 has to be studied in more detail. Many questions 
are open: Is the interaction direct or mediated by other factors? Which are the 
domains responsible for the interaction of the proteins? Is there a competition 
between p53 and Ppan for binding to Hdm2? And more important: Does Ppan 
possibly interact with p53? Further interaction partners, which play a role in sensing 
cellular stress have to be investigated. It would be interesting to know if Ppan could 
interact with the ribosomal proteins S7, L5, L11 and L23, the main signal agents of 
stress-disrupted nucleoli and contribute to a complex of stress-regulated proteins, a 
“stressosome”. Preliminary results show that the mutant PpanΔσ70 is able to 
translocate NPM and hRrp6 from nucleoli to the nucleoplasm.  Are NPM and hRrp6 
binding partners of Ppan in the nucleolus? What would be the relevance of an 
interaction of Ppan with the exosome component hRrp6? Is Ppan needed to position 
the exosome at aberrant rRNA intermediates? 
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Fig. 45. Models for Ppan action in unstressed cells (a) and after inhibition of rDNA 
transcription (b) or rRNA processing (c) (for details see text). 
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Can p53 be stabilized after inhibition of rRNA processing of even rDNA transcription 
in a ppan negative backround? Which morphology would have the segregated 
nucleoli after ActD in cells treated with ppan-specific siRNA? Is Ppan needed for the 
re-establishment of the normal nucleolar structure after the inhibition of transcription 
has been removed? 
The mechanism of Ppan to stabilize p53 may play a role in the response to 
abnormalities in ribosomal biogenesis that could occur during tumor development. 
Preventing the Ppan-Hdm2 interaction may therefore contribute to cancer 
development by inhibition or decrease of p53 activation in response to these types of 
stress signals. A more complete understanding of how Ppan is serving the cell could 
reveal novel targets for the development of therapies, aiming a reactivation of p53. 
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